Published in final edited form as:

J Med Chem. 2016 September 8; 59(17): 7856–7876. doi:10.1021/acs.jmedchem.6b00594.

Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-*d*] Pyrimidine Antifolates with Heteroatom Bridge Substitutions Via Cellular Uptake by Folate Receptor α and the Proton-coupled Folate Transporter and Inhibition of *De Novo* Purine Nucleotide Biosynthesis

Lalit K. Golani^{£,φ}, Adrienne Wallace-Povirk^{||,φ}, Siobhan M. Deis[¥], Jennifer E. Wong[¥], Jiyuan Ke[€], Xin Gu[€], Sudhir Raghavan[£], Mike R. Wilson[‡], Xinxin Li[£], Lisa Polin^{||,‡}, Parker W. de Waal[€], Kathryn White^{||,‡}, Juiwanna Kushner^{||,‡}, Carrie O'Connor^{||}, Zhanjun Hou^{||,‡}, H. Eric Xu^{€,Ω}, Karsten Melcher[€], Charles E. Dann III^{¥,*}, Larry H. Matherly^{*,||,‡,§,θ}, and Aleem Gangjee^{£,*,θ}

^{£,*}Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282

^{||}Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, 110 East Warren Ave, Detroit, MI 48201

[‡]Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201

[§]Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201

[¥]Department of Chemistry, Indiana University, Bloomington, IN 47405

[€]Laboratory of Structural Sciences and Laboratory of Structural Biology and Biochemistry, Van Andel Research Institute, 333 Bostwick Ave NE, Grand Rapids, MI 49503

^ΩKey Laboratory of Receptor Research, VARI-SIMM Center, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, People's Republic of China

*Corresponding Authors: Aleem Gangjee, PhD, 412-396-6070; 412-396-5593 fax; gangjee@duq.edu, Larry H. Matherly, PhD, 313-578-4280; 313-578-4287 fax; matherly@karmanos.org, Charles E. Dann III, PhD, 812-856-1704; 812-856-5710 fax; cedann@indiana.edu.

^{φ,θ}These authors contributed equally to this work.

Notes

The authors declare no competing financial interest.

PDB ID codes: FR α /Cpd **4** PDB ID: 51ZQ; GARFTase/Cpd **4**/ β -GAR PDB ID: 5J9F.

Authors will release the atomic coordinates and experimental data upon article publication.

Competing Interests: The authors declare that they have no competing interests. Atomic coordinates and structure factors for the reported crystal structures of FR α and GARFTase in complex with compound **4** has been deposited in the Protein Data Bank (PDB ID codes 51ZQ and 5J9F, respectively; see Table S2, Supporting Information). Authors will release the atomic coordinates and experimental data upon article publication.

Supporting Information Available: Elemental Analysis, X-ray diffraction data and refinement statistics and Figure 1S; graphs of antifolate concentration against initial slope of GARFTase activity; ¹H NMR spectra of final compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Abstract

Targeted antifolates with heteroatom replacements of the carbon vicinal to the phenyl ring in **1** by N (**4**), O (**8**), or S (**9**), or with N-substituted formyl (**5**), acetyl (**6**), or trifluoroacetyl (**7**) moieties, were synthesized and tested for selective cellular uptake by folate receptor (FR) α and β or the proton-coupled folate transporter. Results show increased *in vitro* anti-proliferative activity toward engineered Chinese hamster ovary cells expressing FRs by **4–9** over the CH₂ analog **1**. Compounds **4–9** inhibited *de novo* purine biosynthesis and glycinamide ribonucleotide formyltransferase (GARFTase). X-ray crystal structures for **4** with FR α and GARFTase showed that the bound conformations of **4** required flexibility for attachment to both FR α and GARFTase. In mice bearing IGROV1 ovarian tumor xenografts, **4** was highly efficacious. Our results establish that heteroatom substitutions in the 3-atom bridge region of 6-substituted pyrrolo[2,3-*d*]pyrimidines related to **1** provide targeted antifolates that warrant further evaluation as anticancer agents.

Graphical abstract

INTRODUCTION

Reduced folates are essential cofactors for biosynthesis of purines and pyrimidines.¹ Since humans do not synthesize folate, it is necessary to obtain these cofactors from dietary sources. In mammals, three specialized systems exist that mediate membrane transport of folates and antifolates across biological membranes. These include the reduced folate carrier (RFC),² folate receptor (FRs) α and β ,³ and the proton-coupled folate transporter (PCFT).^{4, 5} RFC and PCFT are facilitative folate transporters, whereas FRs are glycosylphosphatidylinositol-linked proteins that mediate uptake of folates into cells by receptor-mediated endocytosis. RFC is ubiquitously expressed and is the major tissue transporter for folate cofactors.² FR α and FR β , as well as PCFT, exhibit narrower patterns of tissue expression and likely serve more specialized physiologic roles.^{3, 5} For instance, in the proximal tubules of the kidney, FR α contributes to reabsorption of folate from the urine.³ Notably, FRs in normal tissues are either inaccessible to circulating folates (e.g., FR α in renal tubules) or are non-functional (FR β in thymus).³ PCFT is expressed in the upper gastrointestinal tract where it functions at acidic pH as the major intestinal transporter for absorption of dietary folates.^{6–8} Although appreciable PCFT can be detected in a number of other normal tissues (e.g., liver, kidney),⁵ given the requirement for an acidic pH (pH < 7, optimum at pH 5–5.5) for activity,^{4, 8} PCFT transport should be limited in most normal tissues.

Classical antifolates continue to serve a key role in the therapy of cancer, as well as for other diseases.^{9–13} Clinically important antifolates include methotrexate (MTX), pemetrexed (PMX), pralatrexate (PDX) and raltitrexed (RTX) (Figure 1). MTX and PDX are both inhibitors of dihydrofolate reductase.¹⁰ PMX and RTX inhibit thymidylate synthase as their primary intracellular target, although for PMX, secondary targets have been described, including 5-aminoimidazole-4-carboxamide (AICA) ribonucleotide formyltransferase (AICARFTase) and glycineamide ribonucleotide (GAR) formyltransferase (GARFTase) in *de novo* purine nucleotide biosynthesis, and dihydrofolate reductase.^{14–16} Notably, all these compounds are excellent substrates for the RFC and, to varying degrees, are also substrates for FRs α and β and for PCFT.^{2, 5, 10} Transport by RFC confers limited tumor selectivity, as both tumors and normal tissues express this transporter.² Interestingly, a substantial cohort of solid tumors (e.g., ovarian, non-small cell lung cancer) also expresses PCFT, often in concert with FR α .^{17, 18, 19} In tumors (unlike normal tissues), FR α is accessible to the circulation, thus facilitating tumor targeting via this mechanism.^{20, 21} FR β is expressed in hematologic malignancies such as acute myeloid leukemia³ and in white blood cells of the myeloid lineage,³ including tumor-associated macrophages (TAMs).²² PCFT is active at the acidic pHs typically associated with the tumor microenvironment which confers an additional element of tumor selectivity.⁵

In response to the patterns of expression and function of FRs and PCFT in tumors and normal tissues, new cytotoxic agents are being developed for selective tumor targeting by virtue of their specificities for FRs and/or PCFT. FR β -positive TAMs may play an important role in the tumor microenvironment in relation to tumor metastasis and angiogenesis by releasing proangiogenic factors (e.g., vascular endothelial growth factor, matrix metalloproteinase),²³ suggesting that TAMs may constitute an additional potential therapeutic target in cancer for FR β -targeted agents.²²

Folate and pterate conjugates have been used to deliver cytotoxic agents to FR-expressing tumors including ovarian cancer and non-small cell lung cancer (NSCLC).^{21, 24, 25} For example, a folic acid-vindesine conjugate (vintafolide) was developed which is internalized by FRs, then cleaved in endosomes to release the cytotoxic vinca alkaloid.^{24, 25} Based on its success in a randomized Phase II clinical trial with platinum resistant ovarian cancer,²⁶ vintafolide was advanced to a Phase III clinical trial. More recently, a folic acid-tubulysin conjugate,^{25, 27} was introduced into Phase I clinical trials. *N*-[4-[2-propyn-1-yl]-(6*S*)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3*H*-cyclopenta[*g*]quinazolin-6-yl]amino]benzoyl]-*L*- γ -glutamyl-D-glutamic acid (ONX0801) is a small molecule antifolate with selective substrate activity toward FRs over RFC that is an inhibitor of thymidylate synthase.²⁸ This compound is currently being tested in a Phase I clinical trial.

We previously described novel 6-substituted pyrrolo[2,3-*d*]pyrimidine benzoyl antifolates with selective cellular uptake by FRs and/or PCFT over RFC, resulting in potent inhibitory activity toward human tumor cells.^{18, 29–35} The most active analog of this series, **1**, included a 3 carbon bridge (Figure 2) and showed high level activity toward KB human tumors (IC₅₀ = 1.7 nM)²⁹ expressing FR α and PCFT. Compound **2** has a 4-carbon bridge and showed a better selectivity than **1** for both FR α and PCFT over RFC. An analog of compound **1** with a side-chain thienoyl-for-benzoyl replacement (compound **3**) (Figure 2) showed even greater

FR- and PCFT-targeted activity.³¹ Although **1** and **3** were not effective substrates for RFC, an apparent non-mediated uptake process, as reflected in growth inhibition of both RFC and transport-null cells, was detected.^{29, 31} Compounds **1**, **2** and **3** were identified as potent inhibitors of cellular GARFTase and *de novo* purine nucleotide biosynthesis.^{29, 31} Notably, these compounds were entirely unique from previously reported GARFTase inhibitors including lometrexol [(6R)5,10-dideazatetrahydrofolate; LMTX],³⁶ (2S)-2-((5-(2-((6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl)ethyl)thiophene-2-carbonyl)amino) pentanedioic acid (LY309887),³⁶ and (2S)-2-((5-(2-((6S)-2-amino-4-oxo-1,6,7,8-tetrahydropyrimido[5,4-b][1,4]thiazin-6-yl)ethyl) thiophene-2-carbonyl)amino) pentanedioic acid (AG2034),³⁷ as all these latter antifolates are excellent substrates for RFC. In Phase I clinical trials with these earlier antifolates, toxicities were dose-limiting,^{38–40} likely due at least in part to their cellular uptake by RFC and their metabolism to polyglutamates in normal tissues.

The natural substrate for GARFTase, N10-formyl tetrahydrofolate (10-CHOTHF, Figure 3), is a 6-substituted pteridine with a –CH₂-N-two-atom bridge. The N10 is substituted with a formyl moiety which forms a hydroxylated, tetrahedral intermediate prior to transfer of the one-carbon group.⁴¹ Thus, replacement of the C10-benzylic CH₂ of the 6-substituted pyrrolo[2,3-*d*]pyrimidine **1** with a NH, N-COCH₃, N-CHO, and N-COCF₃ [**4**, **5**, **6**, and **7**, respectively; Figure 4] would afford “mimics” of the natural substrate with a three-atom rather than two-atom bridge. We hypothesized that these 6-substituted three-atom bridged NH and N-substituted analogs would function as potent inhibitors of human GARFTase rather than as substrates. It was further anticipated that these N10-H (**4**) and N10-substituted compounds (**5–7**) would provide additional hydrogen bonding with the target enzyme GARFTase that would be absent with the threecarbon bridge analog **1**.

We previously reported that in the carbon-bridged analogs the length of the side-chain plays an important role in determining potency and transport selectivity^{18, 29} such that the most transport selective analogs have a four-carbon bridge (e.g., **2**) and the most potent GARFTase and tumor inhibitors have a three carbon bridge (e.g., **1**). Thus, it was of interest to compare the effects of replacing the benzylic CH₂ of **1** with NH (compound **4**), O (compound **8**) and S (compound **9**) (Figures 4 and 5). The C-S bond length is 1.81 Å, compared to the C-C bond length of 1.54 Å.⁴² Replacing the benzylic CH₂ of the three-atom chain of **1** with larger sulfur would afford a chain length between those for the 3-carbon and 4-carbon bridges of **1** and **2**, respectively. In addition to the increased bond length, the C-S-C bond angle is 99° compared to a C-C-C bond angle of 109° (Figure 5).⁴² This provides a slightly different conformational orientation of the benzene ring, and hence *L*-glutamate orientation. Similarly, replacement of the benzylic CH₂ with NH or an O would afford subtle variations in bond length (C-O = 1.43 Å) and bond angle (C-O-C = 111°, Figure 5). Collectively, these structural alterations could impact transport selectivity, as well as GARFTase inhibition and antitumor efficacy.

In this study, we report the synthesis and biological activities of analogs of **1** with isosteric heteroatom replacements, including S (**9**), O (**8**) and N (**4**) vicinal to the side chain phenyl ring, along with additional N-substituted analogs including formyl (**5**), acetyl (**6**) and trifluoroacetyl (**7**) moieties.

MOLECULAR MODELING

To provide a rationale for our proposed analogs, molecular modeling studies were initially carried out using our X-ray crystal structure of human GARFTase bound to **3** (PDB: 4ZYW).¹⁸ Figure 6A shows the docked pose of the lead compound **1** (green) in the GARFTase active site as a representative example of docking the target molecules. Compound **4** (orange) is also docked in Figure 6A. The pyrrolo[2,3-*d*]pyrimidine scaffold of **1** binds in the region occupied by the bicyclic scaffold of **3** in the GARFTase crystal structure (PDB: 4ZYW¹⁸, **3** not shown for clarity). Hydrogen bonds between the N1 nitrogen of **1** and the backbone of Leu899, 2-NH₂ of **1** and the carbonyls of Glu948 and Leu899, N3 of **1** and the amide of Ala947, and 4-oxo of **1** and the amide of Asp951 stabilize the scaffold. Additionally, the N7-nitrogen of **1** forms a hydrogen bond with the carbonyl of Arg897. The pyrrolo[2,3-*d*]pyrimidine scaffold of **1** forms hydrophobic interactions with Leu892, Ile898, Leu899, and Val904, and the folate binding loop residues 948–951. The amide NH of the *L*-glutamate of **1** forms a hydrogen bond with the carbonyl of Met896. The *L*-glutamyl moiety of **1** is oriented similar to **3**, with the α -carboxylate interacting with Arg897.

The docked poses of **4** (Figure 6A, orange) and **7** (Figure 6B) retain the hydrogen bonding and hydrophobic interactions seen in the docked pose of the lead compound **1**. In addition, the docked pose of **4** at the N10-H forms hydrogen bonds with the substrate GAR and with Asn913, His915 and Asp951 via a bridging water molecule (Figure 6A). Similar water molecules are seen in other reported X-ray crystal structures of GARFTase.^{18, 44} This suggests that **4** with the N10-H hydrogen bond would possibly bind better than **1** and **2** with C10-H. Docking scores of **4** (–56.31 kJ/mol) were better than those of **1** (–51.26 kJ/mol) and **2** (–52.57 kJ/mol). Similar interactions are predicted to occur between the heteroatom bridges of **8** (oxygen) and **9** (sulfur) and the conserved water molecule, with the heteroatoms functioning as hydrogen bond acceptors (not shown).

The N10-COCF₃ moiety in **7** (Figure 6B) is oriented similar to the N10-H of **4**, but binds deeper into the formyl transfer region that is occupied by the formyl group of the natural GARFTase substrate, 10-CHOTHF. The increased bulk at the N10-position of **7** displaces the water molecule involved in H-bonding with the N10-H of **4**, and affords direct interaction between the trifluoromethyl of the NCOCF₃ moiety of **7** and the terminal amine of substrate GAR. The docking score of **7** in GARFTase was –53.31 kJ/mol. Similar interactions involving the terminal amine of GAR are also observed with the carbonyl of the formyl group of **5** and the carbonyl group of the acetyl of **6** (not shown).

Figure 7 shows the results of molecular modeling studies in the folate binding cleft of FR α (PDB: 4LRH)⁴⁵ for lead compounds **1** (panel A), **2** (panel B) and **4** (panel C). All three compounds display similar interactions in the pocket, maintaining important protein contacts between the bicyclic scaffolds and benzoyl glutamate tail, as also seen in the crystal structure ligand folic acid.⁴⁵ In the docked pose of **4** (Figure 7C), the 2-NH₂ of **4** interacts with Asp103 (81) (for FR, numbering is that of the full-length gene product with mature protein numbering in parentheses). The 4-oxo moiety forms hydrogen bonds with the side chain hydroxyl of Ser196 (174) and the side chain nitrogens of Arg125 (103) and His157

(135). The pyrrolo[2,3-*d*]pyrimidine scaffold is stacked between the side chains of Tyr82 (60) and Trp193 (171), similar to that seen with the pteroyl ring of folic acid in its bound conformation.⁴⁵ The *L*-glutamate moiety of **4** is oriented similar to the corresponding *L*-glutamate in folic acid.⁴⁵ The α -carboxylic acid of **4** forms a network of hydrogen bonds involving the backbone NH of Gly159 (137) and Trp160 (138), while the γ -carboxylic acid of **4** interacts with the amine of Lys158 (136) and the side chain NH of Trp124 (102). The bridge of **4** forms hydrophobic interactions with Tyr82 (60), Phe84 (62), Trp124 (102) and His157 (135).

Comparing the docked poses of **1** (Figure 7A) and **2** (Figure 7B) with the crystal structure of folic acid in FR α ⁴⁵ indicates that the 3- and 4-atom bridges of **1** and **2** are accommodated within a similar space as the 2-atom bridge in folic acid. Since the bridge NH in folic acid does not form hydrogen bonds with the binding pocket, its replacement with an all-carbon bridge (**1** and **2**) could, perhaps, better utilize the hydrophobic nature of the pocket for binding interactions. Introduction of heteroatom bridges in the target compounds was not expected to affect FR α transport capabilities of these compounds, reflected by their highly similar docked pose (*e.g.*, compound **4**, Figure 7C) compared to lead **1** and folic acid. The docking score of **4** was -43.87 kJ/mol, similar to the docked scores of **1** (-44.29 kJ/mol) and **2** (-46.99 kJ/mol).

CHEMISTRY

Compounds **10** and **11** (Scheme I) were subjected to Michael addition to afford the β -keto amine **12**. Compound **12** was then selectively brominated at the α carbon under acidic conditions using 33% HBr in acetic acid/Br₂ to give **13**. Protection of the amine in **13** using trifluoroacetic anhydride and subsequent condensation with 2,6-diamino-3*H*-pyrimidin-4-one in DMF at room temperature for 3 days afforded the 2-amino-4-oxo-6-substituted-pyrrolo[2,3-*d*]pyrimidine **14**. Hydrolysis of **14** afforded the corresponding free acid **15**. Subsequent coupling with *L*-glutamate di-*tert*-butyl ester using 2-chloro-4,6-dimethoxy-1,3,5-triazine as the activating agent afforded the diester **16**. Deprotection of the di-*tert*-butyl ester afforded the corresponding acid **4**. Compound **4** was then reacted with formic acid and acetic anhydride, acetic anhydride or trifluoroacetic anhydride to afford target compounds **5**, **6** and **7**, respectively.

Carboxylic acid **19** (Scheme II) was obtained from β -propiolactone **17** and methyl 4-hydroxybenzoate **18** using NaOH at 50 °C for 30 min. The carboxylic acid **19** was then converted to the acid chloride and immediately reacted with diazomethane, followed by 48% HBr in water, to give the α -bromomethylketone **20**. Condensation of 2,6-diamino-3*H*-pyrimidin-4-one with **20** in DMF at room temperature for 3 days afforded the 2-amino-4-oxo-6-substituted-pyrrolo[2,3-*d*]pyrimidine **21**. Hydrolysis of **21** afforded the corresponding free acid **22**. Subsequent coupling with the *L*-glutamate dimethyl ester using 2-chloro-4,6-dimethoxy-1,3,5-triazine as the activating agent afforded the diester **23**. Saponification of the diester gave the target compound **8**.

The 6-substituted pyrrolo[2,3-*d*]pyrimidine **27** (Scheme III) was synthesized by condensation of 2,6-diamino-4-oxopyrimidine **25** with ethyl 4-chloro-3-oxobutanoate **26**.

Reduction of the ester group of **27** to the alcohol **28** and subsequent mesylation of the alcohol gave **29**. Nucleophilic displacement with 4-mercapto-benzoic acid methyl ester under basic conditions gave the thiophene-linked ester **30**. Hydrolysis of the ester moiety of **30** to acid **31** and coupling with *L*-glutamate diethyl ester using 2-chloro-4,6-dimethoxy-1,3,5-triazine as the activating agent afforded the diester **32**. Saponication of the diester moieties gave target **9**.

BIOLOGICAL EVALUATION AND DISCUSSION

Anti-proliferative effects of 6-substituted pyrrolo[2,3-*d*]pyrimidine benozyl analogs with heteroatom bridge substitutions in relation to mechanisms of folate transport

The goal of this study was to explore the impact of various isosteric heteroatom substitutions including N, O, and S (designated compounds **4**, **8**, and **9**, respectively) at position 10 in the bridge region connecting the bicyclic scaffold and the phenyl ring of 6-pyrrolo[2,3-*d*]pyrimidine antifolates (Figure 4). Additional N-substituted analogs related to **4** with formyl (**5**), acetyl (**6**), and trifluoroacetyl (**7**) substitutions were also synthesized and tested.

As a primary screen of antiproliferative activities for these novel agents, we initially used a panel of isogenic Chinese hamster ovary (CHO) sublines individually expressing FR α (RT16 cells),²⁹ FR β (D4),²⁹ RFC (PC43-10),⁴⁶ or PCFT (R2/PCFT4)⁴⁷. These engineered CHO cell lines were developed from RFC-, FR- and PCFT-null MTXRIIOua^{R2-4} CHO cells⁴⁸ (hereafter, referred to as R2) by stably transfecting the human transporters and have been documented for their transport characteristics.^{29, 46, 47, 49} To assess the inhibitory potentials of the 6-substituted pyrrolo[2,3-*d*]pyrimidine analogs (or classical antifolate inhibitors such as PMX, for comparison), the CHO sublines were cultured in the presence of a range of drug concentrations for up to 96 hours and cell viabilities were measured as a fluorescence read-out. IC₅₀ values, corresponding to the drug concentrations that inhibit growth by 50%, were calculated. Results for the engineered CHO sublines were compared to those for R2 CHO cells.

The 6-substituted pyrrolo[2,3-*d*]pyrimidine analogs with heteroatom bridge replacements, **4** (N), **8** (O), and **9** (S), all showed potent growth inhibition toward FR α -expressing RT16 cells and toward FR β -expressing D4 cells with IC₅₀ values equal or less than those previously reported for **1**^{29, 49} (Table 1). The impacts of N-substitutions including formyl (**5**), acetyl (**6**) or trifluoroacetyl (**7**) on FR-targeted activity compared to N-unsubstituted **4** were modest. Notably, the N-heteroatom analogs including unsubstituted (**4**) and N-substituted (**5** and **6**) forms were significantly more potent toward D4 than toward RT16 cells (<0.003) (Table 1). While **7** was also more active toward D4 cells, the difference from RT16 was not statistically significant. These results suggest an increased FR β selectivity over FR α for the N heteroatom series of 6- substituted pyrrolo[2,3-*d*]pyrimidine analogs.

With PCFT-expressing R2/PCFT4 CHO cells, anti-proliferative activities were reduced for **4** (N), **8** (O) and **9** (S), compared to that for compound **1** (Table 1). N-substitution of **4** (i.e., **5**, **6**, and **7**) resulted in no significant increase in growth inhibition of R2/PCFT4 cells compared to the non-substituted compound (**4**).

Toward RFC-expressing PC43-10 cells, very minor inhibitory effects were detected for all the heteroatom compounds, with IC₅₀s which were far in excess of the inhibition recorded for FR α -, FR β - or PCFT-expressing CHO cells (Table 1). The modest inhibitions of the heteroatom analogs were likewise less than those previously reported toward PC43-10 cells for **1**²⁹ or **3**³¹. Thus, the selectivity for this series (as reflected in the relative IC₅₀s for FR α or FR β versus RFC-expressing CHO cells) is greater than previously reported for compounds **1**, **2** or **3**.^{29, 31}

The results with the engineered CHO sublines were generally recapitulated in KB human nasopharyngeal carcinoma cells, which express FR α and PCFT along with RFC¹⁸, although there were some differences, with **4** and **8** showing potencies essentially equivalent to **3** in this tumor model (Table 1). In KB tumor cells, **4** was significantly more active than **5**, **6**, **7**, and **9** ($p < 0.05$), with the antiproliferative effects for the entire series substantially reversed in the presence of 200 nM folic acid. This is consistent with a FR-mediated cellular uptake process, although non-FR uptake (i.e., PCFT) manifested (as reflected by a lack of folic acid protection¹⁸) at higher concentrations of **4**, **6**, **7** and **8** (Figure 10 shows results for KB cells).

The inhibitory potencies measured for the 6-substituted pyrrolo[2,3-*d*]pyrimidine heteroatom compounds **4**, **5**, **6**, **7**, **8**, and **9** toward the engineered CHO and human tumor cell lines exceeded those for standard antifolates including MTX, PMX, RTX and LMTX (Table 1). Further, there was limited selectivity for FR and PCFT over RFC for the standard agents.

Transport characteristics of 6-substituted pyrrolo[2,3-*d*]pyrimidine benzoyle analogs with heteroatom bridge substitutions

The growth inhibition data with the engineered CHO cell lines in Table 1 strongly imply that the heteroatom analogs **4–9** are internalized by FR α and FR β , as well as by PCFT.

The binding affinity for folic acid, as reflected in the dissociation constant (K_d) value measured by isothermal calorimetry, was greater for FR α ($K_d = 0.01$ nM) than for FR β ($K_d = 2.7$ nM).⁵⁰ To determine relative binding affinities individually for FR α and FR β compared to folic acid for this series, we incubated RT16 and D4 cells with [³H]folic acid at 4 °C in the presence of a range of concentrations of the unlabeled pyrrolo[2,3-*d*]pyrimidine antifolates **1** and **4–9** (0–1000 nM).

Controls for these experiments included a comparable concentration range of non-radioactive folic acid (positive control) and MTX (negative control). Relative binding affinities are reflected in the extents to which the analogs compete with [³H]folic acid for binding to FR, with FR-bound [³H]folic acid normalized to total cell proteins. Relative FR binding affinities were expressed as inverse molar ratios of the unlabeled compounds required to reduce the level of FR-bound [³H]folic acid by 50%, with the folic acid affinity assigned a value of 1.

In this assay, with both FR α - and FR β -expressing cells, relative binding profiles for **4**, **8**, and **9** were similar and ~60–110% of the affinity for folic acid (Figure 8). These results indicate that heteroatom substitution for the benzylic CH₂ in **1** preserves binding affinity for

both FR α (RT16) and FR β (D4). For FR α , the N-formyl-substituted **5** and the N-acetyl- and N-trifluoroacetyl-substituted **6** and **7**, respectively, all showed binding that was substantially reduced (<15% of that for folic acid and for **4**). A similar pattern was detected with FR β -expressing D4 cells and **4**, **5**, **6**, and **7**, in spite of increased *in vitro* drug efficacies toward D4 over RT16 cells (Table 1). Thus, relative FR binding affinities were only *partly* reflected in the differences in *in vitro* drug efficacies toward RT16 or D4 cells (Table 1), suggesting that factors unrelated to FR binding are necessary to explain the differential drug sensitivities at low nanomolar or subnanomolar concentrations of these novel antifolates.

Since the 6-substituted pyrrolo[2,3-*d*]pyrimidine heteroatom compounds were transported by PCFT in R2/PCFT4 CHO cells (based on patterns of growth inhibition; Table 1), we determined relative binding affinities for this series compared to PMX in order to assess a possible basis for differences in relative PCFT-targeted activities. We compared the effects of the heteroatom compounds (at 1 or 10 μ M) on PCFT-mediated transport of [^{3} H]MTX (0.5 μ M) over 5 min at pH 5.5 (the pH optimum of PCFT) and at pH 6.8 (approximating the pH of tumor microenvironment) ⁵ (Figure 9). Results were compared to those for PMX, among the best PCFT substrates,^{4, 5} and for PT523 (N(α)-(4-amino-4-deoxypteroyl)-N(δ)-hemiphthaloyl-L-ornithine), ³⁰ an antifolate substrate for RFC with no significant transport by PCFT. At pH 5.5, PMX potently inhibited [^{3} H]MTX uptake (90% at both 1 and 10 μ M), whereas **4**, **5**, **6**, **7**, **8**, and **9**, like **1** were somewhat less inhibitory (80–90% inhibition at 10 μ M and 30–60% inhibition at 1 μ M). At pH 6.8, inhibitions for all compounds were decreased, although appreciable transport inhibitions (~40–60%) compared to controls were detected at 10 μ M for compounds **1**, **4**, **7** and **8**. K_i values were calculated from the extent of [^{3} H]MTX transport inhibition at pH 5.5 over a range of drug concentrations by Dixon analysis (Table, Figure 9). K_i values ranged from ~7-fold (for **8**) to ~18-fold (for **6**) higher than for PMX. Thus, the patterns of growth inhibition toward PCFT-expressing R2/PCFT4 cells are only partially reflected in analog binding to PCFT.

Identification of GARFTase as the intracellular enzyme target of 6-substituted pyrrolo [2,3-*d*]pyrimidine antifolates with heteroatom bridge substitutions

To identify the targeted pathway, we determined the effects of nucleoside additions on the growth inhibitory effects of compounds **4–9** toward KB tumor cells. The results are shown in Figure 10 and are summarized in Table 1. The antiproliferative effects of all compounds were abolished by adenosine (60 μ M) but not by thymidine (10 μ M), identifying *de novo* purine nucleotide rather than thymidylate biosynthesis as the targeted pathway, analogous to **1**.²⁹ Since AICA (320 μ M), a precursor of AICA ribonucleotide (ZMP) which circumvents the step catalyzed by GARFTase (by providing downstream substrate for AICARFTase, the 2nd folate-dependent reaction) also protected (Figure 10), the likely enzyme target is GARFTase.

We used both *in situ* cell-based (in KB tumor cells) and *in vitro* GARFTase assays with recombinant GARFTase to confirm GARFTase as the enzyme target for our analogs. The former measures the generation of [^{14} C]formyl GAR from [^{14} C]glycine (and GAR) by GARFTase in KB cells treated with azaserine. In these experiments, we incubated KB cells with a range of concentrations of compounds **4–9** and [^{14} C]glycine for 16 h, under

conditions approximating those in our proliferation experiments (Table 1). Our results demonstrated dramatically decreased [^{14}C]formyl GAR in cells in drug-treated cells, with nanomolar IC_{50} values approximating or slightly exceeding those for inhibition of cell proliferation (Figure 11).

We used an *in vitro* spectrophotometric enzyme assay with recombinant formyltransferase domain of human GARFTase to measure inhibition by monoglutamyl 6-pyrrolo[2,3-*d*]pyrimidine antifolates, **1**, **4**, **5**, **6**, **7**, **8**, and **9**, along with **3** and PMX from our previous study.¹⁸ Absorbance was measured at 295 nm accompanying one-carbon transfer from 10-formyl-5,8-dideazafolic acid to GAR to form 5,8-dideazafolic acid and formyl GAR. Assays were performed in the presence and absence of the inhibitors, and the initial rates were plotted versus inhibitor concentrations and fit to a hyperbola (Figure 1S, Supporting Information) for calculating K_i values (Table 2). Nanomolar K_i values were calculated that varied over a ~3–4-fold range, with the most potent GARFTase inhibition by compounds **4**, **6**, and **8**.

Collectively, our results identify GARFTase, the first folate-dependent step in *de novo* purine biosynthesis, as the principal intracellular target for the heteroatom series. The data in Table 2 suggest that as the monoglutamate forms, heteroatom substitution with N (**4**) or O (**8**) affords an approximately 3-fold improvement in GARFTase inhibitory potency over C (**1**). In addition, N-acetyl substitution (**6**) maintains this inhibitory potency. The formyl (**5**) and trifluoroacetyl (**7**) N-substitutions decrease potency somewhat against isolated GARFTase. Further, all of the heteroatom analogs, **4–9**, as well as the carbon analogs **1** and **3**, are 5- to 17-fold better GARFTase inhibitors than PMX.

X-Ray crystal structure of 6-pyrrolo[2,3-*d*]pyrimidine heteroatom antifolates with FR α and human GARFTase

Since compound **4** is selectively transported via FR α over RFC, we determined the x-ray crystal structure of FR α bound to **4** using our published methods.⁴⁵ We expressed human FR α in HEK293 cells and purified FR α by affinity and size-exclusion chromatography. To confirm functionality of the purified soluble FR α , we measured competition for binding to purified FR α by folic acid or **4** with [^3H]folic acid. Compound **4** showed an IC_{50} only slightly higher than that of folic acid in this assay (not shown), consistent with the results of our FR α binding experiments in RT16 CHO cells (Figure 8). For structural determinations, FR α was deglycosylated, stripped of bound folate, then incubated overnight with a molar excess of **4**. The complex was purified and used to set up crystallization screens. The FR α /compound **4** complex formed crystals that permitted the determination of its structure at a resolution of 3.6 Å.

Compound **4** assumes a position in the pocket very similar to that of folic acid (Figures 12A and 12B) with interactions with the same 12 key residues [Tyr82 (60), Asp103 (81), Tyr107 (85), Trp124 (102), Arg125 (103), Arg128 (106), His157 (135), Lys158 (136), Trp160 (138), Trp162 (140), Ser196 (174), and Tyr197 (175); again, numbering for FR α is that of the full-length gene product with mature protein numbering in parentheses]. When compound **4** was computationally docked into the FR α pocket (Figure 7C), the position of the docked **4** was

very close (RMSD 0.37 Å) to that of **4** in the experimentally determined FR α /**4** co-crystal (Figure 12).

As **4** was shown to exhibit nanomolar to sub-nanomolar potencies at GARFTase in our *in situ* and *in vitro* assays, we also determined the structure of a ternary complex of human GARFTase, **4** and substrate GAR (Figure 13; Table 1S, Supporting Information) to further understand the molecular determinants of inhibitor binding. Based on computational modeling (Figure 6A), we hypothesized that **4** would bind in a mode similar to that of **3**, with the only difference being in the positions of the glutamyl α - and γ -carboxylates. Indeed, the pyrrolo[2,3-*d*]pyrimidine portion of **4** makes the predicted polar contacts with backbone atoms from GARFTase residues Ile898, Leu899, Ala947, Glu948 and Val950, whereas the *L*-glutamate of **4** (via the α -carboxylate) is positioned to make a bidentate interaction with Arg897 (Figure 13A). The heteroatom position, N10 in **4**, also makes the predicted intermolecular interaction with GARFTase, mediated by an ordered water molecule that is coordinated by residues Asn913, His915 and Asp951, and the terminal NH₂ of GAR. Based on the crystal structure of the ternary complex of GARFTase with **4** and GAR, and our molecular modeling studies, we predict that other heteroatoms at the 10-position, as seen in **8** (O) and **9** (S) will form hydrogen bonds to the ordered water, as well. N10-substituted compounds, on the other hand (*i.e.*, **5**, **6** and **7**), would likely displace the ordered water and perhaps GAR, as well, while making direct polar contacts with residues Asn913, His915 and Asp951.

We previously reported that the computationally docked structures of our potent targeted molecules had different conformational requirements for attachment to FR α and GARFTase (or AICARFTase).^{35, 51} Superimposition of the crystallographic bound structures of **4** in FR α and GARFTase also shows that diametrically opposite conformations of the side chain of **4** are required for FR α (up) and GARFTase (down) binding. Thus, flexibility in the side chain of **4** is required for attachment to FR α and GARFTase to afford targeted transport and selective tumor inhibition.

***In vivo* antitumor efficacy with **4** with IGROV1 cells**

Based on the *in vitro* efficacies of **4** versus **3** toward KB human tumor cells, we extended this analysis to IGROV1 human ovarian tumor cells. IGROV1 cells express ~40% of FR α levels and exhibit ~30% of PCFT activity of KB cells.¹⁸ We initially compared *in vitro* efficacies of **4** to **3** toward IGROV1 cells as a prelude to an *in vivo* efficacy trial with IGROV1 xenografts (Figure 14, panel A). Compound **3** was selected for comparison, reflecting its highly potent activity toward a broad spectrum of tumors including IGROV1.³¹ Results are also shown for compound **1** with a benzylic CH₂ at position 10. With **3**, an IC₅₀ of 0.95 [$\pm$ 0.35 (SE)] nM was measured that shifted to 213 ($\pm$ 8) nM in the presence of 200 nM folic acid¹⁸, likely in part due to a non-mediated uptake component and to PCFT. Compound **4** was somewhat less potent (likely reflecting decreased non-mediated and PCFT-mediated uptake), with an IC₅₀ of 2.70 ($\pm$ 1.15) nM, and protection by folic acid was substantially increased (IC₅₀=872 $\pm$ 106 nM). Similar results were seen with compound **1** toward IGROV1 cells (IC₅₀ of 4.1 ($\pm$ 1.7) nM), although the inhibition was further reversed (IC₅₀ >1000 nM) in the presence of excess folic acid.

For the *in vivo* drug efficacy trial, female NCR severe-combined immunodeficient (SCID) mice implanted bilaterally with subcutaneous IGROV1 ovarian tumors. Mice were provided a folate-deficient diet *ad libitum* to reduce serum folate concentrations to levels similar to those reported in humans.⁵² A parallel control cohort included mice fed standard (folate-replete) chow. For the trial, both the control and low-folate groups were implanted subcutaneously with IGROV1 tumor fragments. Compound **3** (Q3dx5; 28 mg/kg/inj) or compound **4** (Q3dx4; 96 and 150 mg/kg/inj) was administered intravenously beginning on day 2 post-implantation. The highest doses of **3** and **4** administered approximated the maximally tolerated doses for these compounds. The tumors were measured (twice weekly) and the overall health and body weights of the mice were recorded daily.

For the mice maintained on the folate-deficient diet, **3** (140 mg/kg total dose) was efficacious, with a 35% T/C on day 20, T-C of 9 days, and 1.4 log₁₀ kill, as previously described.³¹ Compound **4** was tested at two dose levels. The highest non-toxic total dose of 600 mg/kg produced significant antitumor activity (12% T/C; T-C=15 days; 2.3 log₁₀ kill), whereas the lower dose (384 mg/kg total dose) showed an efficacy similar to compound **3** (29% T/C; T-C=9 days, 1.4 log₁₀ kill). These results demonstrate not only a dose-response but an efficacious depth-of-activity (favorable therapeutic index) for compound **4**. For all treatments, the regimens were well tolerated, and the only dose-limiting symptom (weight loss) was completely reversible. Body weight loss (nadir of 15% for compound **3** and 17.0–17.3% for compound **4**) occurred while the mice were undergoing treatment. However, following treatment, full weight recovery occurred within 48 hours. For the matched control group maintained on a standard diet, antitumor activity was ablated; i.e., compound **3** (140 mg/kg total dose) and compound **4** (600 mg/kg total dose) produced T/C values of 68% and 94% respectively. No weight loss or other adverse symptoms were observed.

The results from the *in vivo* efficacy trial with FR α - and PCFT-expressing IGROV1 human ovarian tumors substantiate our *in vitro* drug efficacy results and demonstrate that at *equitoxic* dose levels, **4** is more efficacious than **3**, albeit with a higher dose requirement. Compound **4** showed a good depth-of-activity and there were no acute or long term toxicities other than completely reversible weight loss.

Conclusions

This study describes an in-depth analysis of the structure-activity determinants of 6-substituted pyrrolo[2,3-*d*]pyrimidine benzoyl antifolates as tumor-targeted therapeutics. The focus is on structural determinants involving heteroatom replacements of the carbon vicinal to the side chain phenyl ring in compound **1** by S, O, or N, and for the N-replacement, the impact of N-formyl, N-acetyl, or N-trifluoroacetyl moieties on cell proliferation and anti-tumor efficacy. The emphasis is on determinants of transport specificity by FR α and FR β , and by PCFT, over RFC, and on inhibition of *de novo* purine nucleotide biosynthesis at GARFTase, the first folate-dependent step in this pathway.

Our results document several salient findings including (i) dramatically increased *in vitro* anti-proliferative activity resulting from heteroatom bridge substitutions toward CHO cell lines engineered to express human FR α or FR β and FR α -expressing human tumor cells,

over the corresponding C analog **1**. (ii) For the N-heteroatom unsubstituted and substituted forms (compounds **4–7**), *in vitro* drug efficacies were significantly greater toward FR β -expressing CHO cells than toward CHO cells expressing a comparable amount of FR α . This likely reflects differences in rates of FR-mediated internalization and/or dissociation of bound ligands for FR β versus FR α , as FR-targeted activities for these analogs were only modestly reflected in relative binding affinities to FR α and FR β . FR α binding of **4** was confirmed by x-ray crystallography which validated the molecular modeling predictions for this series. Compared to compound **1**, PCFT targeting was reduced by the heteroatom insertions, as reflected in decreased growth inhibition and decreased competition for [³H]MTX uptake with human PCFT-expressing R2/PCFT4 CHO cells.

We established *de novo* purine nucleotide biosynthesis as the targeted pathway and GARFTase as the enzyme target for the heteroatom-substituted antifolates, as measured by nucleoside/AICA protection from growth inhibition, and by *in situ* metabolic assays with [¹⁴C]glycine. Inhibition of cellular GARFTase in KB cells occurred at concentrations similar to those that inhibit cell proliferation. Results of the metabolic assays were corroborated by *in vitro* assays with purified GARFTase that showed greater enzyme inhibition by analogs with N (**4**, **5**, **6**, and **7**) and O (**8**) insertions than that with a C-10 (**1**). For compound **4**, a crystal structure was determined with GARFTase, providing further validation of this enzyme target and demonstrating clear contacts with the N10 heteroatom analogous to that in 10-CHOTHF. The disparity in drug concentrations for *in vitro* enzyme inhibition versus GARFTase inhibition in the cell-based metabolic assay likely reflects the importance of membrane transport and polyglutamate synthesis, as determinants of drug efficacy in intact cells. The potent *in vitro* inhibition of GARFTase by compounds **3**, **4**, **6** and **8** in their monoglutamate forms suggests that these antifolates would be effective against tumor cells resistant to PMX and other clinically used antifolates due to loss of polyglutamate synthesis, reflecting down regulation and/or deficiency of folylpolyglutamate synthetase.⁵³

We extended our studies with engineered CHO and KB human tumor cells to IGROV1 human tumor cells, a model of serous ovarian cancer with significantly lower levels of FR α and PCFT.¹⁸ In a head-to-head comparison with **3**, a thieonyl 6-substituted pyrrolo[2,3-*d*]pyrimidine and among the most potent FR- and PCFT-targeted agents we have identified,³¹ **4** was *more efficacious at an equitoxic dose*, albeit with a higher dose requirement.

In conclusion, we established that heteroatom substitutions, including S, O and N, in the bridge region of 6-substituted 3-atom bridge pyrrolo[2,3-*d*]pyrimidine analogs related to **1** and **3** exert pronounced effects on the activity of this series, associated with increased targeting via FRs. Compared to clinically used antifolates such as PMX, analogs **4–9** are selectively transported into tumor cells, resulting in potent inhibition of GARFTase and cell proliferation, and would be expected to possess significantly lower toxicity toward normal tissues. In an *in vivo* study with IGROV1 human tumor cells, compound **4** was significantly more efficacious than **3**, the most efficacious analog we have reported previously. Reflecting these characteristics, these novel tumor-targeted antifolates warrant further evaluation as anticancer agents.

EXPERIMENTAL SECTION

A rotary evaporator was used to carry out evaporation *in vacuo*. Final compounds and intermediates were dried in a CHEM-DRY drying apparatus over P₂O₅ at 80 °C. A MEL-TEMP II melting point with a FLUKE 51 K/J electronic thermometer apparatus was used and uncorrected to record melting points. A Bruker WH-400 (400 MHz) spectrometer or a Bruker WH-500 (500 MHz) spectrometer was used to record proton nuclear magnetic resonance spectra (¹H NMR). Tetramethylsilane was used as an internal standard to express the chemical shift in ppm (parts per million): s, singlet; d, doublet; t, triplet; q, quartet; quin, quintet m, multiplet; and bs, broad singlet. Chemical names follow IUPAC nomenclature. Whatman Sil G/UV254 silica gel plates with a fluorescent indicator were used for performing thin-layer chromatography (TLC), and the spots were visualized under 254 nm and 365 nm illumination. All analytical samples were homogeneous on TLC in three different solvent systems. Solvents used for TLC were measured in volume. Columns of silica gel (230–400 mesh) (Fisher, Somerville, NJ) were used for chromatography. In spite of 24–48 h of drying *in vacuo*, fractional moles of water found in the analytical samples of antifolates could not be prevented and were confirmed by their presence in the ¹H NMR spectra. Chemicals and solvents were purchased from Aldrich Chemical Co. or Fisher Scientific Co. and were used as received. Elemental analysis (C, H, N, F, S) was performed by Atlantic Microlab, Inc. (Norcross, GA). Element compositions were within 0.4% of the calculated values and confirmed >95% purity for all the compounds submitted for biological evaluation (Supporting Information is in Table 1S)

(4-([2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]amino)benzoyl)-L-glutamic acid (**4**)

To a 100 mL rbf compound **15** (100 mg, 0.32 mmol), *N*-methylmorpholine (0.64 mmol), 2-chloro-4,6-dimethoxy-1,3,5-triazine (0.64 mmol) and anhydrous DMF (7 mL) were added. The resulting mixture was stirred at room temperature under anhydrous condition for 1.5 hours. *N*-methylmorpholine (0.64 mmol) and *L*-glutamate di-tert-butyl hydrochloride (0.47 mmol) were added in reaction mixture. The resulting mixture was then stirred at room temperature under anhydrous condition for 12 hours. After evaporation of solvent under reduced pressure, MeOH (20 mL) was added followed by silica gel (1 gm). The resulting plug was loaded on to a silica gel column (3.5 cm × 2 cm) and eluted with CHCl₃ followed by 3% MeOH in CHCl₃. Fractions with *R_f* = 0.45 (MeOH/CHCl₃ 5:1) were pooled and evaporated to afford **16** (106 mg, 0.19 mmol, yield 60%) as solid. Compound **16** (106 mg, 0.19 mmol) was dissolved in dichloromethane (10 mL) and trifluoroacetic acid (2 mL) was added. The mixture was stirred at room temperature for 2 hours. TLC showed the disappearance of the starting material (*R_f* = 0.45) and one major spot at the origin (MeOH/CHCl₃ 5:1). The solvent was removed under reduced pressure and the residue was dissolved in 1 N NaOH. The suspension was filtered and filtrate was acidified to pH 4 with 1 N HCl. The resulting suspension was frozen in dry ice/acetone bath, thawed to 4–5 °C in the refrigerator, and filtered. The residue was washed with a small amount of cold water and dried in vacuum using P₂O₅ to afford the target compound **4** (63 mg, yield 74%) as yellow powder; m.p. 163 °C; ¹H NMR (DMSO-*d*₆) δ 1.93–2.07 (m, 2H, β-CH₂), 2.32–2.33 (m, 2H, γ-CH₂), 2.74–2.77 (t, 1H, CH₂CH₂NH, *J* = 6.0 Hz), 3.29–3.32 (t, 2H, CH₂CH₂NH, *J* = 6.0

Hz), 4.32–4.38 (m, 1H, α -CH), 5.99 (d, 1H, C5-CH, $J = 2.0$ Hz), 6.03 (d, 2H, 2-NH₂, exch.), 6.27 (s, 1H, CH₂CH₂NHAr, exch.), 6.60–6.62 (d, 2H, Ar-CH, $J = 8$ Hz), 7.66–7.68 (d, 2H, Ar-CH, $J = 8$ Hz), 8.13–8.15 (d, 1H, Ar-CONH, $J = 8$ Hz, exch.), 10.18 (bs, H, 3-NH, exch.), 10.93 (s, H, 7-NH, exch.). Anal. Calcd for (C₂₀H₂₂N₆O₆·1.75 H₂O) C, H, N.

(4-{N-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]formamido}benzoyl)-L-glutamic acid (5)

To a solution of **4** (110 mg, 0.25 mmol) in 97% formic acid (5 mL) was added acetic anhydride (0.07 mL, 15.75 mmol), and the reaction mixture was stirred at 25 °C for 3 hours. The solvent was removed under reduced pressure and the residue dissolved in 1 N NaOH at 0 °C. The filtrate was acidified to pH 4 with 0.5 N HCl and stored at 0 °C for 2 hours. The yellow solid was collected by filtration and dried over P₂O₅ to give 40 mg (35%) of **5**; m.p. 163 °C; ¹H NMR (DMSO-*d*₆) δ 1.95–2.13 (m, 2H, β -CH₂), 2.34–2.37 (t, 2H, γ -CH₂, $J = 7.2$ Hz), 2.68–2.72 (t, 2H, CH₂CH₂NCOH, $J = 7.2$ Hz), 4.06–4.09 (t, 2H, CH₂CH₂NCOH, $J = 7.2$ Hz), 4.38–4.44 (m, 1H, α -CH), 5.91 (s, 1H, C5-CH), 6.08 (bs, 2H, 2-NH₂, exch.), 7.41–7.43 (d, 2H, Ar-CH, $J = 8.4$ Hz), 7.93–7.95 (d, 2H, Ar-CH, $J = 8.4$ Hz), 8.57 (s, CH₂CH₂NCOH, 1H), 8.64–8.66 (d, 1H, Ar-CONH, $J = 7.6$ Hz), 10.23 (bs, H, 3-NH, exch.), 10.93 (s, H, 7-NH, exch.). Anal. Calcd for (C₂₁H₂₂N₆O₇·2H₂O·0.4CF₃COOH) C, H, N.

(4-{N-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]acetamido}benzoyl)-L-glutamic acid (6)

4 (110 mg, 0.25 mmol) was added in 5 mL acetic anhydride, and the reaction mixture was stirred under anhydrous condition at 25 °C for 3 hours. The excess of acetic anhydride was removed under reduced pressure. The residue was suspended in cold water and basified using 1N NaOH. The suspension was then filtered and acidified to pH 4 with 0.5 N HCl and stored at 0 °C for 2 hours. The white solid was collected by filtration and dried over P₂O₅ to give 57 mg (47%) of **6**; m.p. 163 °C; ¹H NMR (DMSO-*d*₆) δ 1.93–2.14 (m, 5H, β -CH₂ & CH₂CH₂NCOCH₃), 2.35–2.39 (m, 2H, γ -CH₂), 2.64–2.67 (t, 2H, CH₂CH₂NCOCH₃, $J = 8$ Hz), 3.89–3.92 (t, 2H, CH₂CH₂NCOCH₃, $J = 8$ Hz), 4.38–4.44 (m, 1H, α -CH), 5.91 (s, 1H, ArH), 5.99 (s, 2H, 2-NH₂, exch.), 7.34–7.36 (d, 2H, Ar-CH, $J = 8$ Hz), 7.93–7.95 (d, 2H, Ar-CH, $J = 8$ Hz), 8.68–8.70 (d, 1H, Ar-CONH, $J = 8$ Hz, exch.), 10.16 (bs, H, 3-NH, exch.), 10.83 (s, H, 7-NH, exch.). Anal. Calcd for (C₂₂H₂₄N₆O₇·2H₂O) C, H, N.

(4-{N-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]-2,2,2-trifluoroacetamido}benzoyl)-L-glutamic acid (7)

5 mL trifluoroacetic anhydride was added to a solution of **4** (110 mg, 0.25 mmol) in 10 mL dichloromethane, and the reaction mixture was stirred at 25 °C for 3 hours. The solvent was removed under reduced pressure and the residue was suspended in water. 1N NaOH was added dropwise to the suspension and pH was adjusted to 4. The suspension was stored at 0 °C for 2 hours. The yellow solid was collected by filtration and dried over P₂O₅ to give 83 mg (76%) of **7**; m.p. 163 °C; ¹H NMR (DMSO-*d*₆) δ 1.96–2.12 (m, 2H, β -CH₂), 2.36–2.39 (t, 2H, γ -CH₂, $J = 7.2$ Hz), 2.73–2.77 (t, 2H, CH₂CH₂NCOCF₃, $J = 7.6$ Hz), 3.95–3.99 (t, 2H, CH₂CH₂NCOCF₃, $J = 7.6$ Hz), 4.38–4.44 (m, 1H, α -CH), 6.00 (s, 1H, C5-CH), 6.10 (bs, 2H, 2-NH₂, exch.), 7.40–7.42 (d, 2H, Ar-CH, $J = 8$ Hz), 7.94–7.96 (d, 2H, Ar-CH, $J =$

8 Hz), 8.77–8.79 (d, 1H, Ar-CONH, J = 7.4 Hz, exch.), 10.25 (bs, H, 3-NH, exch.), 10.91 (s, H, 7-NH, exch.), 12.33 (bs, 2H, 2COOH, exch.). Anal. Calcd for (C₂₂H₂₁N₆O₇F₃·1H₂O·0.06CF₃COOH) C, H, N, F.

{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-*d*]pyrimidin-6-yl)ethoxy]benzoyl}-L-glutamic acid (8)

To a 250 mL rbf, was added a mixture of **22** (100 mg, 0.32 mmol), *N*-methylmorpholine (0.64 mmol), 2-chloro-4,6-dimethoxy-1,3,5-triazine (0.64 mmol) and anhydrous DMF (7 mL). After 1.5 hour *N*-methylmorpholine (0.64 mmol) and *L*-glutamic acid dimethylester hydrochloride (0.5 mmol). The reaction mixture was then stirred at room temperature for 12 hours. After evaporation of solvent under reduced pressure, MeOH (20 mL) was added followed by silica gel (1 gm). The resulting plug was loaded on to a silica gel column (3.5 × 2 cm²) and eluted with CHCl₃ followed by 3 % MeOH in CHCl₃. Fractions with R_f = 0.42 (CHCl₃/CH₃OH, 5:1) were pooled and evaporated to afford **23** (63 mg, yield 42%).

Compound **20** (0.13 mmol) was dissolved in MeOH (10 mL) added 1N NaOH (10 mL) and the mixture was stirred under anhydrous condition at room temperature for 10 h. TLC showed the disappearance of the starting material (R_f = 0.42) and one major spot at the origin (MeOH/CHCl₃ 5:1). The reaction mixture was dissolved in water (10 mL), the resulting solution was cooled in an ice bath, and the pH was adjusted to 3–4 with dropwise addition of 1N HCl. The resulting suspension was frozen in dry ice-acetone bath, thawed to 4–5 °C in the refrigerator, and filtered. The residue was washed with a small amount of cold water and dried in vacuum using P₂O₅ to afford the target compound **8 (8)** (55 mg, 0.12 mmol) as white powder; m.p. 162 °C; ¹H NMR (DMSO-*d*₆) δ 1.95–2.11 (m, 2H, β-CH₂), 2.34–2.37 (t, 2H, γ-CH₂, J = 6.0 Hz), 2.97–3.00 (t, 2H, CH₂CH₂O, J = 6.0 Hz), 4.24–4.27 (t, 2H, CH₂CH₂O, J = 6.0 Hz), 4.36–4.41 (m, H, α-CH), 6.00 (s, H, C5-CH), 6.01 (bs, 2H, 2-NH₂, exch.), 7.03–7.05 (d, 2H, Ar-CH, J = 8.0 Hz), 7.86–7.88 (d, 2H, Ar-CH, J = 8.0 Hz), 8.45–8.47 (d, 1H, Ar-CONH, J = 8.0 Hz), 10.23 (s, H, 3-NH, exch.), 10.97 (s, H, 7-NH, exch.), 12.39 (bs, 2H, 2COOH, exch.). Anal. Calcd for (C₂₀H₂₁N₅O₇·2 H₂O) C, H, N.

(4-{[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-*d*]pyrimidin-6-yl)ethyl]thio}benzoyl)-L-glutamic acid (9)

To a solution of the **3** (309 mg, 0.6 mmol) in MeOH (10 mL) was added 1N NaOH (10 mL) and the mixture was stirred at room temperature for 10 h. The reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in distilled water (5 mL), and the pH was adjusted to 3–4 by dropwise addition of 1N HCl. The precipitate was filtered, washed with water and dried under vacuum with P₂O₅ to afford 260 mg (95%) of **9** as a light yellow powder. mp 184–185 °C; ¹H NMR (DMSO-*d*₆): δ 1.92–2.12 (m, 2H, β-CH₂), 2.34–2.37 (t, 2H, γ-CH₂, J = 7.5 Hz), 2.82–2.85 (t, 2H, CH₂CH₂S, J = 7.5 Hz), 3.29–3.32 (t, CH₂CH₂S J = 7.5 Hz, 2H, CH₂), 4.37–4.42 (m, 1H, α-CH), 6.00 (s, 1H, C5-CH), 6.02 (s, 2H, 2-NH₂, exch), 7.41–7.43 (d, J = 8.5 Hz, Ar-CH), 7.83–7.85 (d, J = 8.5 Hz, Ar-CH), 8.56–8.58 (d, J = 8.0 Hz, 1H, Ar-CONH, exch), 10.17 (s, 1H, 3-NH, exch), 10.91 (s, 1H, 7-NH, exch), 12.46 (bs, 2H, COOH, exch). Anal. Calcd for (C₂₀H₂₁N₅O₆S·1.0 H₂O) C, H, N, S.

Ethyl 4-[(3-oxobutyl)amino]benzoate (12)

To a vigorously stirred solution of compound **11** (5 gm, 30 mmol) in anhydrous absolute ethanol (10 mL), methyl vinyl ketone **10** (2.5 mL) was added. The reaction mixture was heated under reflux for 4.5 hours and resultant mixture was cooled to 0 °C. The precipitated crystalline product was collected and washed with precooled ethanol and dried to afford **12** (4.2 gm, yield 59%) as white powder; m.p. 98 °C; R_f 0.57 (1:1 hexane:EtOAc); ^1H NMR (CHCl_3) δ 1.36–1.39 (t, 3H, OCH_2CH_3 , $J = 7.2$ Hz), 2.19 (s, 3H, CH_2COCH_3), 2.79–2.82 (t, 2H, $\text{CH}_2\text{CH}_2\text{O}$, $J = 6.0$ Hz), 3.48–3.51 (t, 2H, $\text{CH}_2\text{CH}_2\text{O}$, $J = 6.0$ Hz), 4.31–4.36 (q, 2H, OCH_2CH_3 , $J = 7.2$ Hz), 5.54 (bs, Ar-NH, exch.), 6.61–6.64 (d, 2H, Ar-CH, $J = 8.4$ Hz), 7.88–7.91 (d, 2H, Ar-CH, $J = 8.4$ Hz).

Ethyl 4-[(4-bromo-3-oxobutyl)amino]benzoate (13)

A suspension of **12** (3 gm, 12.77 mmol) in 8 mL of 33% hydrogen bromide-glacial acetic acid solution was treated with 1 mL of bromine in 2 mL of glacial acetic acid and stirred for 2.5 hours at 25 °C. Ether (100 mL) was added to the reaction mixture with swirling until separation of the syrupy hydrobromide was complete. The ether was decanted, and any ether remaining was evaporated from the syrup along with excess hydrogen bromide. After further drying by evaporation (bath 35 °C) of a solution in an equal volume of dichloromethane, the syrup weighed 3.3 gm. The syrup was then stirred with cold water and filtered to afford yellow solid. Yellow solid obtained was then washed with water (3×20 mL) and dissolved in dichloromethane. The solution was dried over sodium sulfate. Removal of solvent under reduced pressure at room temperature gave a beige colored semisolid. The crude product was thoroughly triturated with pre-cooled ether and the solid product was collected by filtration to afford **13** (1.75 gm, yield 33%); m.p. 142 °C; R_f 0.81 (1:1 hexane:EtOAc); ^1H NMR (CHCl_3) δ 1.37–1.41 (t, 3H, OCH_2CH_3 , $J = 7.2$ Hz), 2.79–2.82 (t, 2H, $\text{CH}_2\text{CH}_2\text{O}$, $J = 6.0$ Hz), 3.48–3.51 (t, 2H, $\text{CH}_2\text{CH}_2\text{O}$, $J = 6.0$ Hz), 3.91 (s, 2H, $\text{CH}_2\text{COCH}_2\text{Br}$), 4.33–4.38 (q, 2H, OCH_2CH_3 , $J = 7.2$ Hz), 6.82–6.84 (d, 2H, Ar-CH, $J = 8.4$ Hz), 7.94–7.96 (d, 2H, Ar-CH, $J = 8.4$ Hz).

4-[[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]amino]benzoic acid (15)

A suspension of α -bromoketone **13** (11.89 gm, 38 mmol) in trifluoroacetic anhydride (100 mL) was stirred under anhydrous condition at room temperature to give a clear solution within 30 minutes. The stirring continued for an additional 2 hours and the solution was allowed to stand at room temperature overnight. After removal of excess trifluoroacetic anhydride under reduced pressure at 40–45 °C, the brownish oily residue was dissolved in dichloromethane (150 mL). The solution was washed with cold 2% HCl (100 mL), cold 5% NaHCO_3 (100 mL), and finally with cold water (2×100 mL). The organic layer was then treated with a mixture of Florisil-charcoal- sodium sulfate (59 gm: 2.4 gm: 20 gm) and stirred for 0.5 hour at room temperature. The mixture was filtered and excess of solvent was evaporated under reduced pressure at 25–30 °C to afford amine protected α -bromoketone (11.31 gm, yield 76%). Amine protected α -bromoketone (3.84 gm, 9.4 mmol) was then added to a suspension of 2,6-diaminopyrimidin-4-one (1.26 gm, 10 mmol) in anhydrous dimethylformamide (25 mL). The resulting mixture was stirred under anhydrous condition at

room temperature for 3 days. After evaporation of solvent under reduced pressure, Methanol (20 mL) was added followed by silica gel (5 gm). The resulting plug was loaded on to a silica gel column (3.5 cm × 12 cm) and eluted with CHCl₃ followed by 3% MeOH in CHCl₃ and then 5% MeOH in CHCl₃. Fractions with and R_f = 0.58 (TLC) (CHCl₃/CH₃OH, 5:1) were pooled and evaporated to afford **14** (1.03 gm, 2.36 mmol, yield; 25%). Compound **14** (306 mg, 0.7 mmol) was dissolved in MeOH (10 mL) and 1N NaOH (10 mL) was added. The mixture was stirred under anhydrous condition at room temperature for 10 hours. TLC showed disappearance of the starting material (R_f = 0.45) and one major spot at the origin (MeOH/CHCl₃ 5:1). The reaction mixture was dissolved in water (10 mL), the resulting solution was cooled in an ice bath, and the pH was adjusted to 3–4 with drop wise addition of 1N HCl. The resulting suspension was frozen in dry ice-acetone bath, thawed to 4–5 °C in the refrigerator, and filtered. The residue was washed with a small amount of cold water and dried in vacuum using P₂O₅ to afford compound **15** (157 mg, yield 88%) as yellow powder.

Compound **14**; m.p. 157 °C; ¹H NMR (DMSO-*d*₆) δ 1.25–1.29 (t, 3H, OCH₂CH₃, J = 7.2 Hz), 2.75–2.78 (t, 2H, CH₂CH₂NCOCF₃, J = 6.0 Hz), 3.31–3.35 (t, 2H, CH₂CH₂NCOCF₃, J = 6.0 Hz), 4.18–4.23 (q, 2H, OCH₂CH₃, J = 7.2 Hz), 6.00 (s, 1H, C5-CH), 6.01 (bs, 2H, 2-NH₂), 6.62–6.64 (d, 2H, Ar-CH, J = 8 Hz), 7.68–7.70 (d, 2H, Ar-CH, J = 8 Hz), 10.25 (s, H, 3-NH), 10.97 (s, H, 7-NH).

Compound **15**; m.p. 177 °C; ¹H NMR (DMSO-*d*₆) δ 2.74–2.77 (t, 1H, CH₂CH₂NH, J = 6.0 Hz), 3.29–3.32 (t, 2H, CH₂CH₂NH, J = 6.0 Hz), 5.98 (s, 1H, C5-CH), 6.11 (bs, 2H, 2-NH₂, exch.), 6.54 (t, 1H, CH₂CH₂NH, exch.), 6.60–6.62 (d, 2H, Ar-CH, J = 8 Hz), 7.65–7.68 (d, 2H, Ar-CH, J = 8 Hz), 10.25 (s, H, 3-NH, exch.), 10.94 (s, H, 7-NH, exch.). Anal. Calcd for (C₁₅H₁₅N₅O₃·0.2CHCl₃·2.5CH₃COOH) C, H, N.

3-[4-(ethoxycarbonyl)phenoxy]propanoic acid (**19**)

To 100 mL of distilled water in an Erlenmeyer flask was added 4.15 gm (25 mmol) of **18** and the mixture was slowly heated to 80 °C under stirring with the dropwise addition of 25 mL of 1 N NaOH. The clear solution thus obtained was treated with 2 mL of β-propiolactone **17**, and the mixture was allowed to stir at this temperature for 0.5 hours. The solution was then cooled to room temperature and acidified with 6N HCl to pH 3. The precipitated material was extracted with three 25 mL portions of ether, and the ether extract was washed twice with distilled water and extracted several times with 20 mL portions of saturated sodium bicarbonate until all the effervescence ceased on further addition of NaHCO₃. The bicarbonate extracts were combined and acidified to pH 3 with 6 N HCl. The white precipitate thus obtained was washed with water and dried to afford compound **19** (3.18 gm, 52%); m.p. 146–147 °C; R_f 0.51 (Hexane/EtOAc 1:1); ¹H NMR (CDCl₃): δ 2.89–2.92 (t, 2 H, CH₂CH₂O, J = 6.0 Hz), 3.91 (s, 3H, OCH₃), 4.31–4.34 (t, 2 H, CH₂CH₂O, J = 6.0 Hz), 6.94–6.95 (d, 2 H, Ar-CH, J = 7.5 Hz), 8.00–8.02 (d, 2 H, Ar-CH, J = 7.5 Hz).

4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-*d*]pyrimidin-6-yl)ethoxy]benzoic acid (**22**)

To **19** (2.24 gm, 10 mmol) in a 250 mL flask was added oxalyl chloride (7.61 gm, 60 mmol) and anhydrous CH₂Cl₂ (20 mL). The resulting solution was refluxed for 1 hour and then cooled to room temperature. After the solvent was evaporated under reduced pressure, the

residue was dissolved in 20 mL of Et₂O. The resulting solution was added dropwise to an ice cooled diazomethane (generated in situ from 15 gm of diazald by using Aldrich Mini Diazald apparatus) in an ice bath over 10 min. The resulting mixture was allowed to stand for 30 min and then stirred for an additional 1 hour. To this solution was added 48% HBr (20 mL). The resulting mixture was refluxed for 1.5 hours. After the mixture was cooled to room temperature, the organic layer was separated, and the aqueous layer was extracted with Et₂O (2 × 200 mL). The combined organic layer and Et₂O extract was washed with two portions of 10% Na₂CO₃ solution and dried over Na₂SO₄. Evaporation of the solvent afforded **20** (2.82 gm, 9.4 mmol) in 94% yield. To a suspension of 2,6-diaminopyrimidin-4-one (1.26 gm, 10 mmol) in anhydrous DMF (25 mL) were added **20** (2.82 gm, 9.4 mmol). The resulting mixture was stirred under N₂ at room temperature for 3 days. After evaporation of solvent under reduced pressure, MeOH (20 mL) was added followed by silica gel (5 gm). The resulting plug was loaded on to a silica gel column (3.5 cm × 12 cm) and eluted with CHCl₃ followed by 3% MeOH in CHCl₃ and then 5% MeOH in CHCl₃ (CHCl₃/CH₃OH, 5:1). Fractions with *R_f* 0.58 (TLC) were pooled and evaporated to afford **21** (956 gm, yield 31%) as white powder. Compound **21** (0.7 mmol) was dissolved in MeOH (10 mL) added 1N NaOH (10 mL) and the mixture was stirred under anhydrous condition at room temperature for 10 hours. TLC showed the disappearance of the starting material (*R_f* = 0.58) and one major spot at the origin (MeOH/CHCl₃ 5:1). The reaction mixture was dissolved in water (10 mL), the resulting solution was cooled in an ice bath, and the pH was adjusted to 3–4 with dropwise addition of 1N HCl. The resulting suspension was frozen in dry ice-acetone bath, thawed to 4–5 °C in the refrigerator, and filtered. The residue was washed with a small amount of cold water and dried in vacuum using P₂O₅ to afford the target **22** (677 mg, yield 74%) as white powder; m.p.; 159 °C, ¹H NMR (DMSO-*d*₆) δ 2.97–2.99 (t, 2H, CH₂CH₂O, *J* = 6.0 Hz), 4.25–4.28 (t, 2H, CH₂CH₂O, *J* = 6.0 Hz), 6.01 (s, H, C5-CH), 6.26 (bs, 2H, 2-NH₂, exch.), 7.04–7.06 (d, 2H, Ar-CH, *J* = 8.0 Hz), 7.88–7.90 (d, 2H, Ar-CH, *J* = 8.0 Hz), 10.35 (s, H, 3-NH, exch.), 11.04 (s, H, 7-NH, exch.). Anal. Calcd for (C₁₅H₁₄N₄O₄·0.75 H₂O) C, H, N.

Ethyl 2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-*d*]pyrimidin-6-yl)acetate (**27**)

To a solution of 2,4-diamino-6-hydroxypyrimidine **25**, (7.20 gm, 50 mmol) and sodium acetate (4.10 gm, 50 mmol) in water (150 mL) at reflux was added, dropwise, ethyl-4-chloroacetoacetate, **26** (7.41 mL, 55 mmol). Within an hour, a thick white precipitate appeared. The mixture was heated at reflux for 18 hours. The suspension was cooled to room temperature, filtered, washed with water (2 × 50 mL), acetone (2 × 50 mL) and dried to afford 7.31 gm (54%) of **27** as a buff-colored solid: m.p. >250 °C; ¹H NMR (DMSO-*d*₆) δ 1.16–1.21 (t, 3H, OCH₂CH₃, *J* = 7.2 Hz), 3.57 (s, 2H, Ar -CH₂), 4.04–4.11 (q, 2H, OCH₂CH₃, *J* = 7.2 Hz), 6.00 (s, 1H, C5-CH), 6.04 (bs, 2H, 2-NH₂, exch.), 10.20 (bs, 1H, 3-NH, exch.), 10.90 (bs, 1H, 7-NH, exch.).

2-Amino-6-(2-hydroxyethyl)-3,7-dihydro-4H-pyrrolo[2,3-*d*]pyrimidin-4-one (**28**)

To a suspension of the ester **27** (1.0 gm, 4.24 mmol) in anhydrous tetrahydrofuran (25 mL) at 0 °C was added a 1 M solution of lithium triethylborohydride (Super-Hydride) in tetrahydrofuran (33 mL, 33.92 mmol). The solution was stirred for 30 minutes, after which water (30 mL) was added carefully, followed by acidification of the mixture to pH 5.0 with 5

N hydrochloric acid. Tetrahydrofuran was evaporated under vacuum, and the white precipitate obtained was refrigerated overnight, filtered and dried under vacuum over phosphorous pentoxide to afford 0.615 gm (75%) of **28** as a white solid: m.p. >275 °C; ¹H NMR (DMSO- *d*6) δ 2.60–2.64 (t, 2H, CH₂CH₂OH, *J* = 6.0 Hz), 3.55–3.61 (q, 2H, CH₂CH₂OH, *J* = 6.0 Hz), 4.61–4.64 (bs, 1H, CH₂CH₂OH), 5.88 (s, 1H, C5-CH), 5.96 (bs, 2H, 2-NH₂, exch), 10.12 (bs, 1H, 3-NH, exch), 10.76 (bs, 1H, 7-NH, exch).

2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-*d*]pyrimidin-6-yl)ethyl methanesulfonate (**29**)

To a solution of the alcohol **28** (0.25 gm, 1.29 mmol) in *N,N*-dimethylformamide (20 mL) at 0 °C was added triethylamine (0.27 mL, 1.93 mmol) and methanesulfonyl chloride (0.16 gm, 1.42 mmol) and the solution stirred under nitrogen for 2 hours. The reaction mixture was filtered and the filtrate was evaporated to dryness. The residue was suspended in acetone, silica gel (0.50 gm) was added to the suspension and the acetone evaporated to form a plug, which was loaded on top of a silica gel column (20 cm × 2 cm) and eluted using a 5:1 mixture of chloroform:methanol. Fractions containing the product (*R_f* = 0.41, chloroform:methanol, 3:1) were pooled and the solvent evaporated to afford 0.28 gm (80%) of **29** as a white solid: m.p. >250 °C (dec.); ¹H NMR (DMSO-*d*6) δ 2.89–2.93 (t, 2H, CH₂CH₂OSO₂CH₃, *J* = 6.0 Hz), 3.13 (s, 3H, CH₂CH₂OSO₂CH₃), 4.36–4.41 (t, 2H, CH₂CH₂OSO₂CH₃, *J* = 6.0 Hz), 6.01 (bs, 3H, 2-NH₂ & CH), 10.17 (bs, 1H, 3-NH, exch), 10.91 (bs, 1H, 7-NH, exch).

Methyl 4-[[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-*d*]pyrimidin-6-yl)ethyl]thio]benzoate (**30**)

To a solution of 4-mercaptobenzoic acid methyl ester (907 mg, 5.4 mmol) in anhydrous DMF (20 mL) was added potassium carbonate (1.12 gm, 8.1 mmol), and the mixture was stirred at room temperature under nitrogen. After 1 h, methanesulfonic ester, **25**, (730 mg, 2.7 mmol) was added all at once, and the resulting mixture was stirred for a further 6 h at room temperature. The solvent was evaporated under reduced pressure and the residue was dissolved in methanol. Silica gel (1 gm) was added, and the solvent was evaporated under reduced pressure. The resulting plug was loaded on the top of a silica gel column (2 cm × 15 cm) and eluted using a gradient of with 5–10% MeOH in CHCl₃. Fractions that showed the desired product (TLC) were pooled and evaporated to dryness to afford 344 mg (37%) of **30** as a white powder. m.p. 179–180 °C; TLC *R_f* 0.58 (CHCl₃/MeOH 5:1); ¹H NMR (DMSO-*d*6): δ 2.84–2.87 (t, 2H, CH₂CH₂S, *J* = 7.5 Hz), 3.31–3.34 (t, 2H, CH₂CH₂S, *J* = 7.5 Hz), 6.02 (s, 1H, C5-CH), 6.10 (s, 2H, 2-NH₂, exch), 7.43–7.45 (d, Ar-CH, *J* = 8.5 Hz), 7.86–7.88 (d, Ar-CH, *J* = 8.5 Hz), 10.24 (s, 1H, 3-NH, exch), 10.96 (s, 1H, 7-NH, exch).

4-[[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-*d*]pyrimidin-6-yl)ethyl]thio]benzoic acid (**31**)

To a solution of the **30** (344 mg, 1 mmol) in MeOH (10 mL) was added 1N NaOH (10 mL) and the mixture was stirred at 60 °C for 10 h. The reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in distilled water (5 mL), and the pH was adjusted to 3–4 by dropwise addition of 1N HCl. The precipitate was filtered, washed with water and dried under vacuum with P₂O₅ to afford 330 mg (99%) of **31** as a

light yellow powder. m.p. 189–190 °C; ^1H NMR (DMSO- d_6): δ 2.84–2.87 (t, 2H, $\text{CH}_2\text{CH}_2\text{S}$, $J = 7.5$ Hz), 3.31–3.34 (t, 2H, $\text{CH}_2\text{CH}_2\text{S}$, $J = 7.5$ Hz), 6.04 (s, 1H, C5-CH), 6.25 (s, 2H, 2-NH $_2$, exch), 7.41–7.42 (d, Ar-CH, $J = 8.5$ Hz), 7.85–7.87 (d, Ar-CH, $J = 8.5$ Hz), 10.39 (s, 1H, 3-NH, exch), 11.04 (s, 1H, 7-NH, exch), 12.79 (s, 1H, COOH, exch).

Diethyl (4-[[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-*d*]pyrimidin-6-yl)ethyl]thio}benzoyl)-*L*-glutamate (**32**)

To a solution of **31**, (330 mg, 1 mmol) in anhydrous DMF (20 mL) was added *N*-methylmorpholine (0.2 mL, 1.8 mmol) and 2-chloro-4,6-dimethoxy- 1,3,5-triazine (317 mg, 1.8 mmol). The resulting mixture was stirred at room temperature for 2 h. To this mixture was added *N*-methylmorpholine (0.2 mL, 1.8 mmol) and *L*-glutamic acid diethyl ester hydrochloride (360 mg, 1.5 mmol). The reaction mixture was stirred for an additional 4 h at room temperature and then evaporated to dryness under reduced pressure. The residue was mixed with 1 g of silica gel to make a plug and chromatographed on a silica gel column (2 × 15 cm) with 10% MeOH in CHCl_3 as the eluent. Fractions that showed the desired spot (TLC) were pooled and evaporated to dryness to afford 309 mg (60%) of **32** as a light yellow powder. m.p. 84–85 °C; TLC R_f 0.59 ($\text{CHCl}_3/\text{MeOH}$ 5:1); ^1H NMR (DMSO- d_6): δ 1.15–1.21 (m, 6H, OCH_2CH_3), 1.97–2.15 (m, 2H, $\beta\text{-CH}_2$), 2.43–2.46 (t, 2H, $\gamma\text{-CH}_2$, $J = 7.5$ Hz), 2.82–2.85 (t, 2H, $\text{CH}_2\text{CH}_2\text{S}$, $J = 7.5$ Hz), 3.29–3.33 (t, 2H, $\text{CH}_2\text{CH}_2\text{S}$, $J = 7.5$ Hz), 4.03–4.13 (m, 4H, $2\text{OCH}_2\text{CH}_3$), 4.41–4.45 (m, 1H, C5-CH), 6.00 (s, 1H, C5-CH), 6.15 (s, 2H, 2-NH $_2$, exch), 7.41–7.43 (d, $J = 8.5$ Hz, Ar-CH), 7.83–7.85 (d, $J = 8.5$ Hz, Ar-CH), 8.71–8.72 (d, $J = 7.5$ Hz, 1H, CONH, exch), 10.29 (s, 1H, 3-NH, exch), 10.96 (s, 1H, 7-NH, exch).

Molecular Modeling and Computational Studies

The X-ray crystal structures of human FR α bound to folic acid (PDB: 4LRH, 2.80 Å)⁴⁵ and human GARFTase bound to **3** (PDB: 4ZYW, 2.05 Å)₁₈ were obtained from the protein database. Antifolate GARFTase docking studies were performed using LeadIT 2.1.6.⁵⁴ Default settings were used to calculate the protonation state of the proteins and the ligands. Free rotation of water molecules in the ligand binding site (defined by amino acids within 6.5 Å from the crystal structure ligand) was permitted. Ligands for docking were sketched using MOE 2013.08,⁵⁵ and energy was minimized using the MMF94X force field (limit of 0.05 kcal/mol). Molecules were docked using the triangle matching placement method and scored using default settings. The docked poses were visualized using CCP4MG.⁵⁶

In order to validate the docking process (using LeadIT 2.1.6), the crystallized ligands (folic acid for FR α and compound **3** for GARFTase) were sketched using MOE, energy minimized and docked. Deviation of the best docked poses from the crystal structure conformation was calculated using an RMSD SVL code obtained from the ChemComp website (www.chemcomp.com). The best scored pose of folic acid in FR α had an RMSD of 0.81 Å. Compound **3** in the human GARFTase had an RMSD of 1.04 Å. Thus, LeadIT 2.1.6 was validated for our docking purposes in FR α and human GARFTase.

Compound **4** was docked into a structure of FR α with folic acid removed from the coordinate file (PDB:4LRH), using the standard flexible-ligand sampling algorithm⁵⁷ implemented in DOCK6.72.⁵⁸ Ligand placement was prioritized by the combined grid score

(vdw+es) and the atom footprint similarity was compared to folic acid. Prior to docking, partial charges from the all-atom AMBER ff14SB⁵⁹ were assigned to the receptor and semi-empirical AM1-BCC charges were derived for each antifolate using UCSF chimera.⁶⁰

Reagents for biological studies

[3', 5', 7, 9-³H]Folic acid (25 Ci/mmol), [3', 5', 7-³H]MTX (20 Ci/mmol), and [¹⁴C(U)]-glycine (87mCi/mmol) were purchased from Moravek Biochemicals (Brea, CA). Unlabeled folic acid was purchased from the Sigma-Aldrich (St. Louis, MO). LCV [(6R,S)5-formyl tetrahydrofolate] was provided by the Drug Development Branch, National Cancer Institute (Bethesda, MD). The sources of the classical antifolate drugs were as follows: MTX, Drug Development Branch, National Cancer Institute; LMTX (5,10-dideaza-5,6,7,8-tetrahydrofolate) and PMX [N-{4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid] (Alimta), Eli Lilly and Co. (Indianapolis, IN); RTX [N-(5-[N-(3,4-dihydro-2-methyl-4-oxyquinazolin-6-ylmethyl)-N-methyl-amino]-2-thienoyl)-L-glutamic acid], AstraZeneca Pharmaceuticals (Macclesfield, Cheshire, England); and PT523 [N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine],³⁰ A. Rosowsky (Boston, MA). Other chemicals were obtained from commercial sources in the highest available purities.

Cell lines and assays of antitumor drug activities

The engineered CHO sublines including RFC-, PCFT- and FR α -null MTXR11Oua^R2-4 (R2), and RFC- (pC43-10), PCFT- (R2/PCFT4), or FR α -(RT16) and FR β -(D4) expressing CHO sublines were previously described.^{29, 46–48} The CHO cells were cultured in α -minimal essential medium (MEM) supplemented with 10% bovine calf serum (Invitrogen, Carlsbad, CA), penicillin (1000 U/mL) streptomycin (1000 μ g/mL) and 2 mM *L*-glutamine at 37° C with 5% CO₂. All the R2 transfected cells (PC43-10, RT16, R2/hPCFT4) were cultured in complete α -MEM media plus 1 mg/mL G418. Prior to the cytotoxicity assays (see below), RT16 and D4 cells were cultured for 3 days in complete folatefree RPMI 1640 (without added folate), plus dialyzed fetal bovine serum (FBS) (Sigma-Aldrich) and penicillin/streptomycin. KB human nasopharyngeal carcinoma cells were purchased from the American Type Culture Collection (Manassas, VA). IGROV1 ovarian carcinoma cells were a gift of Dr. Manohar Ratnam (Karmanos Cancer Institute). IGROV1 and KB cells were routinely cultured in folate-free RPMI 1640 medium, supplemented with 10% FBS (Sigma-Aldrich), penicillin-streptomycin solution, and 2 mM *L*-glutamine.

For growth inhibition studies, cells (CHO, KB, IGROV1) were plated in 96 well dishes (~2500–5000 cells/well; total volume of 200 μ l medium) with a range of antifolate concentrations (0–1000 nM).^{31, 61} The experiments with RT16, D4, KB, and IGROV1 cells used folate-free RPMI medium with 10% dialyzed FBS, antibiotics and *L*-glutamine; the medium was supplemented with 2 nM LCV. To confirm FR-mediated drug uptake, 200 nM folic acid was added to parallel incubations. For experiments with R2, PC43-10, and R2/PCFT4 cells, cells were routinely cultured in folate-free RPMI 1640 (pH 7.2)/10% dialyzed FBS with antibiotics and *L*-glutamine, supplemented with 25 nM LCV. Cells were incubated up to 96 h and viable cells were assayed with Cell-Titer Blue^{TM} reagent (Promega, Madison, WI), with fluorescence measured with a fluorescence plate reader. Fluorescence data were

analyzed for calculations of IC_{50} s, corresponding to the drug concentrations that resulted in 50% loss of cell proliferation.

To confirm the targeted pathway/enzyme target, *in vitro* growth inhibition of KB tumor cells was measured in the presence of thymidine (10 μ M) or adenosine (60 μ M).^{29–31, 47} For *de novo* purine biosynthesis, additional protection experiments used AICA (320 μ M) to distinguish inhibitory effects at GARFTase from those at AICARFTase.^{29–31, 47}

FR binding assay

To measure relative binding affinities for antifolate drugs,^{29–31, 47} RT16 (expresses FR α) and D4 (FR β) CHO cells were cultured in 60 mm dishes until they were ~80% confluent. Cells ($2-4 \times 10^6$ cells) were sequentially rinsed at 4°C with Dulbecco's phosphate-buffered saline (DPBS) (3x), followed by acidic buffer (10 mM sodium acetate, 150 mM NaCl, pH 3.5) (2x) (removes FR-bound folates), and finally HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl₂, 5 mM glucose, pH7.4) (HBS). Cells were incubated with [³H]folic acid (50 nM, specific activity 0.5 Ci/mmol) in HBS in the presence and absence of unlabeled folic acid, MTX (negative control), or the 6-pyrrolo[2,3-*d*]pyrimidine antifolates (range of concentrations up to 1000 nM) for 15 min at 0°C. Dishes were rinsed with HBS (0–4°C, 3x). Cells were solubilized with 0.5 N NaOH, and aliquots were measured for radioactivity and protein contents. Protein concentrations were quantified with Folin-phenol reagent.⁶² FR-bound [³H]folic acid was calculated as pmol/mg protein and binding affinities were calculated as the inverse molar ratios of unlabeled ligands required to inhibit [³H]folic acid binding by 50%. The relative affinity of folic acid was assigned a value of 1.

Transport assays

R2 and R2/hPCFT4 CHO sublines were grown in suspension as spinner cultures at densities of $2-5 \times 10^5$ cells/mL. Cells were collected by centrifugation, washed with DPBS, and the cell pellets ($\sim 2 \times 10^7$ cells) were suspended in transport buffer (2 mL) for cellular uptake assays. PCFT-dependent uptake of 0.5 μ M [³H]MTX was assayed in cell suspensions over 2 min at 37° C in HBS at pH 6.8, or in 4-morpholinopropane sulfonic (MES)-buffered saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl₂, and 5 mM glucose) at pH 5.5 in the presence of 1 or 10 μ M inhibitor. At the end of the incubations, transport was quenched with ice-cold DPBS, cells were washed three times with ice-cold DPBS, and cellular proteins were solubilized with 0.5 N NaOH. Levels of drug uptake were expressed as pmol/mg protein, calculated from direct measurements of radioactivity and protein contents of the cell homogenates. Proteins were quantified using Folin-phenol reagent.⁶² Transport results were normalized to levels in untreated controls. For determining K_i values for the 6-pyrrolo[2,3-*d*]pyrimidine antifolates compared to PMX, transport was measured over 2 min with 0.5 μ M [³H]MTX and 0–5 μ M of the unlabeled antifolate. Data were analyzed by Dixon plots.

In situ GARFTase assays

Inhibition of intracellular GARFTase in the presence of antifolate inhibitors was measured by following incorporation of [¹⁴C(U)] glycine into [¹⁴C]formyl GAR in cells treated with

azaserine.^{30, 32, 33, 35, 63} KB cells in 60 mm dishes were washed with folate-free RPMI 1640 (*L*-glutamine-free) with 10% dialyzed FBS, penicillin-streptomycin and 2 nM LCV. Cells were incubated at 37° C for 1 h in folate and *L*-glutamine-free RPMI 1640 media/10% dialyzed FBS (supplemented with 2 nM LCV), with antifolate inhibitors over a range of concentrations. Azaserine (4 μM final) was added and the cells were incubated for 30 min, after which *L*-glutamine (2 mM) and [¹⁴C(U)]glycine (final specific activity 0.1 mCi/L) were added. Cells were incubated an additional 16 h at 37° C, washed with ice-cold DPBS, trypsinized and collected. The cells were treated with 5% trichloroacetic acid (TCA) at 0 37° C, the samples centrifuged (4° C, 14,000 rpm) and the precipitated proteins solubilized (0.5 N NaOH). Proteins were quantified with the Folin-phenol protein method.⁶² The TCA supernatants were extracted with ether at 4° C, and the aqueous layer was fractionated by anion-exchange chromatography on ~1 mL columns of [AG1x8 (chloride form)]. Columns were washed with 10 mL of 0.5 N formic acid, followed by 10 mL of 4 N formic acid; the bound [¹⁴C]formyl GAR was eluted with 1 N HCl as eight 1 mL fractions. The 1 N HCl eluate was quantified for radioactivity and the percentages of radioactivity in the [¹⁴C]formyl GAR and non-specific [¹⁴C]fractions were calculated. Results were expressed as cpm [¹⁴C]formyl GAR/mg cell protein. IC₅₀s corresponding to antifolate concentrations that inhibit accumulation of [¹⁴C]formyl GAR compared to untreated controls were calculated by plotting percent inhibition versus antifolate concentration.

***In vitro* GARFTase assays and K_i determinations**

For *in vitro* enzymatic assays of GARFTase with pyrrolo[2,3-*d*]pyrimidine inhibitors, HisGARFTase (formyltransferase domain), containing an N-terminal cleavable hexahistidine tag, was purified as described previously.¹⁸ GARFTase catalytic activity was measured by following the formation of 5,8-dideazafoate spectrophotometrically from 10-formyl-5,8-dideazafoate in the presence of varying concentrations of antifolate.⁶⁴ Assays included 30 μM α,β-GAR, 5.4 μM 10-formyl-5,8- dideazafoate, and a range of antifolates in 0.1 M Hepes, pH 7.5 (150 μL total volume). Reactions were pre-incubated at 37° C in a UV transparent 96-well plate (Costar) and initiated by adding 150 μL of 20 nM GARFTase or buffer (reference wells). Measurements were recorded at 295 nm every fifteen seconds over twenty minutes using a BioTek Synergy H1M plate reader. Triplicate assays were performed. For determining the initial rate for each drug concentration, absorbance of the reference well was subtracted. Initial rate changes in absorbance at 295 nm were determined and correlation coefficients were compared over appropriate time spans to identify regions over which linear absorbance increases occurred for all replicates. Initial slopes were graphed against the antifolate concentrations and a hyperbola fit [$y = (-a \cdot x / (K_i + x)) + b$, where “a” is the amplitude and “b” is the y-intercept] was used to calculate the K_i value for each compound (KaleidaGraph version 4.1).

***In vivo* efficacy study with IGROV1 human ovarian tumor xenografts**

Protocols for drug treatments, toxicity evaluations, and data analysis using transplantable human cell line xenografts have been previously described.^{30, 31, 65–68} IGROV1 ovarian tumor cells were implanted subcutaneously (5×10^6 cells/flank) to establish a solid tumor xenograft model in female NCR SCID mice (NCI Animal Production Program). For drug efficacy studies, 11 week old mice (20 g average body weight) were provided food and

water *ad libitum*. Mice were fed either a folate-deficient diet (Harlan-Teklad, TD.00434) or a standard (folate-replete) diet (Lab Diet, 5021; autoclavable mouse breeder diet). For the trial, mice were placed on their respective diets 14 days before tumor implant so that the serum folate levels for mice maintained on the folate-deficient diet would approximate those in humans.⁵² A *Lactobacillus casei* bioassay⁶⁹ was used to measure serum folate levels. Mice were pooled for each dietary group and implanted bilaterally subcutaneously with 30–60 mg tumor fragments using a 12 gauge trocar, then unselectively distributed to the various drug treatment and control groups. Drugs were administered by tail vein injection beginning 2 days post-tumor implantation, when the tumors had established blood supply but were below the limit of palpation (63 mg). Tumors were measured with a caliper two-to-three times weekly and mice were weighed and assessed daily. Animals were sacrificed when the cumulative tumor size reached 1500 mg (while still asymptomatic). Tumor weights were estimated from two-dimensional measurements [i.e., tumor mass (in mg) = $(a \times b^2)/2$, where *a* and *b* are the tumor length and width in mm, respectively]; for calculating the endpoints, both tumor masses on each flank were added together. Quantitative end-points to assess anti-tumor activity include: (i) tumor growth delay [T-C, where T is the median time in days required for the treatment group tumors to reach a predetermined size (e.g., 1000 mg), and C is the median time in days for the control group tumors to reach the same size; tumor-free survivors are excluded from these calculations]; and (ii) tumor cell kill [$\log_{10}$ cell kill total (gross) = $(T - C)/(3.32)(T_d)$, where T - C is the tumor growth delay, as described above, and *T_d* is the tumor volume doubling time in days, estimated from the best fit straight line from a log-linear growth plot of control group tumors in exponential growth (100 to 800 mg range)]. A T/C value (in percent) was also determined for each treatment group when treatment (T) and control (C) groups for the control groups reached 700–1200 mg in size (exponential growth phase). The median and mean values for each group was determined (including zeros). T/C is a non-quantitative determination of antitumor activity and the inverse of tumor growth inhibition. Rather, T/C is a measure of antitumor effectiveness based on the specific day of caliper measurement.

Crystallization and X-ray data collection and structure determination of human GARFTase

GARFTaseHis protein (formyltransferase domain; containing a non-cleavable C-terminal hexahistidine) purification and crystallization were performed as described in our previous work.¹⁸ Briefly, purified GARFTaseHis at a concentration of 10 mg/mL in 25 mM Tris (pH 8), 200 mM NaCl and 10 mM β -mercaptoethanol was incubated with a 3-fold molar excess of α , β -GAR and compound **4** (dissolved in DMSO) for 2 h at 4° C. Sitting drop vapor diffusion plates were set up with 1 μ L protein, 1 μ L crystallant and 0.2 μ L of either 32 mM N-nonyl- β -D-thiomaltoside or 9 mM N-decyl- β -D-thiomaltoside (Hampton Research), using 0.1 M Tris (pH 7.5), 0.333 mM NaCl, 18% polyethylene glycol (PEG) 3350, and 2% PEG 400 as the crystallant solution. Plates were incubated at 4° C and crystals formed within a few days. Crystals were cryoprotected via addition of PEG 400 to 14% stepwise via incremental transfers, increasing PEG at 2% per step. Cryoprotectant solutions included α , β -GAR and compound **4** at the same concentration as the initial crystallization mixture. Data collection was performed at the Advanced Photon Source beamline 24-ID-E, part of the Northeastern Collaborative Access Team (NE-CAT). All data sets were processed to a P3₂21 space group using the RAPD data processing protocol implemented at NE-CAT.

Molecular replacement was performed using one chain of 4ZZ1 with ligands and waters removed as a search model (PHENIX).^{70, 71} Subsequent model building and refinement were performed using Coot and PHENIX.^{72, 73} The final GARFTase/compound **4**/β-GAR model was refined to give R_{work} and R_{free} of 17.8 % and 21.5 %, respectively.

Expression and purification of human FRα

Human FRα (23–234) in fusion with a human IgG Fc tag (FRα-FcH6)⁴⁵ was expressed as stable clone in HEK293 cells maintained in 500 mL of Dubecco's minimal essential medium (DMEM) supplemented with 5% FBS, 20 mM HEPES, 5 μM kifunensine, and 200 μM folic acid in 1 L roller bottles at 37° C, as previously described.⁴⁵ Two liters of conditioned medium were collected, concentrated to 400 mL, and dialyzed against TBS buffer (20 mM Tris, pH8.0, 150 mM NaCl, and 5% glycerol) at 4° C overnight before loading on a 50 mL Ni-chelating Sepharose column (GE Healthcare). The column was washed with 300 mL buffer A (25 mM Tris, pH 8.0, 150 mM NaCl, 25 mM imidazole, and 5% glycerol) and eluted with buffer B (25 mM Tris, pH 8.0, 150 mM NaCl, and 500 mM imidazole). The peak fractions were pooled and buffer-exchanged against 20 mM citrate (pH 5.5), 150 mM NaCl, and 5% glycerol for deglycosylation using endoglycosidase Hf (New England Biolabs) at room temperature overnight. The endogenous folic acid ligand was dissociated from FRα-FcH6, as described.⁵⁰ Briefly, the FRα-FcH6 buffer was exchanged against 25 mM acetate (pH 3.5) with 20% FBS and incubated with 0.5 mL active charcoal (Sigma-Aldrich) at room temperature for 15 min. Charcoal was then removed by centrifugation and the pH adjusted to pH 7.5 using 1 M Tris, pH 11. A 6-fold molar excess of compound **4** (relative to protein) was added. The mixture was incubated at 4° C overnight. The **4**/FRα-FcH6 complex was then purified over a 5 mL Nickelating Sepharose column. The peak fractions were pooled, concentrated, buffer-exchanged against TBS buffer with **4** at a final 2x concentration of FRα-FcH6 and subjected to thrombin digestion at a 1:1000 mass ratio at 4° C overnight. The digestion product was loaded on a 5 mL Ni-NTA column to remove the FcH6 tag. The flow-through was collected and was finally separated by Sephadex S-200 gel filtration in buffer C (25 mM Tris, pH 8.0, 200 mM ammonium acetate, 1 mM EDTA). The protein eluted from the gel filtration column at a volume corresponding to the size of a monomer with a purity >95%, as judged by SDS/polyacrylamide gel electrophoresis.

Soluble FRα radioligand-binding assay

The affinities of folic acid and compound **4** were estimated by homologous (folic acid) and heterologous (antifolates) competition assays. First, the endogenous ligand was stripped, as described,⁴⁵ and then exchanged against [³H]folic acid in 100 μL binding buffer (25 mM Tris, pH 8.0, 150 mM NaCl, 0.1% Triton X-100). The FRα/[³H]folic acid complex was then incubated with increasing concentrations of homologous or heterologous competitor, as indicated. Unbound ligands were removed by two 100 μL washes in binding buffer and remaining FRα/[³H]folic acid complex determined by scintillation counting.

FRα crystallization, data collection and structure determination

The purified FRα/compound **4** complex was supplemented with a two-fold molar excess of **4** and concentrated to ~6 mg/mL before setting up crystallization trials using a Phenix

crystallization robot (Art Robbin Instruments) at 20 °C. Commercial screens (Hampton Research) were used for initial high-throughput sitting drop screening in 96-well intelliplates (Rigaku), with a mixture of 0.2 µl protein and 0.2 µl crystallization solution sitting in 50 µl reservoir solution. Once crystals appeared in the initial screen, optimization trays in 24-well VDX plates (Hampton Research) were set up manually using the hanging drop method at 20° C. Crystals were grown at 20° C containing 1 µl of the purified protein and 0.5 µl of well solution [10% (w/v) PEG 10K, 0.1 M BIS-TRIS (pH 6.5), 0.2 M potassium sodium tartrate tetrahydrate]. Crystals appeared in two-to-three weeks and grew to a dimension of ~100 µm length with a cubic shape.

Crystals were transferred to well solution with 20% (v/v) ethylene glycol as a cryoprotectant before flash freezing in liquid nitrogen. Data collection was performed at sector 21-ID-D (LS-CAT) of the APS synchrotron using single crystals and the diffraction data were processed using XDS,⁷⁴ combined using Pointless, and merged using Scala of the CCP4 suite.⁷⁵ According to Matthew's coefficient calculation, the crystals have a large unit cell with eight molecules per asymmetric unit. Eight molecules in one asymmetric unit were located by molecular replacement using Phaser⁷⁶ with the FR α /folic acid crystal structure with ligand removed (PDB code: 4LRH) as a search model. The eight molecules of the FR α models were refined against the diffraction data with 8-fold non-crystallographic symmetry restraints using the Refmac program of CCP4.⁷⁷ The densities for compound **4** became clear after several rounds of model adjustments and refinements and six molecules of compound **4** were built into the final model. The final model was refined to give R_{work} and R_{free} of 22.2 % and 26.5 %, respectively (Table 2S, Supporting Information).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by grants from the National Institutes of Health, CA53535 (LHM and ZH), CA125153 (AG), CA152316 (LHM and AG), CA166711 (AG, LHM and CED), GM094472 (CED), DK071662 (HEX), GM102545 (KM) and GM104212 (KM), National Science Foundation grant NSF91217311 (HEX), the Eunice and Milt Ring Endowed Chair for Cancer Research (LHM), the Duquesne University Adrian Van Kaam Chair in Scholarly Excellence (AG), the Van Andel Research Institute (HEX and KM), and Ministry of Science and Technology (China) grants 2012ZX09301001, 2012CB910403, 2013CB910600, XDB08020303, and 2013ZX09507001. Mr. Wilson was supported by T32 CA009531 (LHM). Ms. Deis was supported by T32 GM007757. The Animal Model and Therapeutics Evaluation Core (AMTEC; LP, KW, JK) was supported, in part, by NIH Center grant P30 CA022453 to the Karmanos Cancer Institute and the Wayne State University. We thank T.S. Widlanski for providing the α , β -GAR substrate for crystallography and enzyme inhibition experiments. All GARFTase crystallization experiments were carried out in the Indiana University METACyt Crystallization Automation Facility. This work is based upon research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P41 GM103403). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357. We thank staff members of the Life Science Collaborative Access Team of the Advanced Photon Source (APS) for assistance in collection of FR α diffraction data 0 at the beam lines of sector 21, which is in part funded by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (Grant 085P1000817). Use of APS was supported by the Office of Science of the US Department of Energy, under Contract No. DE-AC02-06CH11357.

ABBREVIATIONS USED

AICA	5-aminoimidazole-4-carboxamide
AICARFTase	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase
CHO	Chinese hamster ovary
FBS	fetal bovine serum
DMEM	Dulbecco's minimal essential medium
DPBS	Dulbecco's phosphate-buffered saline
FR	folate receptor
10-CHOTHF	N10-formyl tetrahydrofolate
GAR	glycinamide ribonucleotide
GARFTase	glycinamide ribonucleotide formyltransferase
HBSS	Hank's balanced salts solution
HBS	HEPES-buffered saline
LMTX	lometrexol
LCV	leucovorin
MTX	methotrexate
MEM	minimal essential media
PMX	pemetrexed
PEG	polyethylene glycol
PDX	pralatrexate
PCFT	proton-coupled folate transporter
PEG	polyethylene glycol
RTX	raltitrexed
RFC	reduced folate carrier
SCID	severe-combined immunodeficient
TAMs	tumor-associated macrophages
TCA	trichloroacetic acid
TLC	thin layer chromatography

References

1. Stokstad, ELR. Historical Perspective on Key Advances in the Biochemistry and Physiology of Folates. Wiley-Liss; New York: 1990. p. 1-21.
2. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. *Cancer Metastasis Rev.* 2007; 26:111–128. [PubMed: 17334909]
3. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy. *Adv Drug Deliv Rev.* 2004; 56:1067–1084. [PubMed: 15094207]
4. Zhao R, Goldman ID. The molecular identity and characterization of a proton-coupled folate transporter--PCFT; biological ramifications and impact on the activity of pemetrexed. *Cancer Metastasis Rev.* 2007; 26:129–139. [PubMed: 17340171]
5. Desmoulin SK, Hou Z, Gangjee A, Matherly LH. The human proton-coupled folate transporter: Biology and therapeutic applications to cancer. *Cancer Biol Ther.* 2012; 13:1355–1373. [PubMed: 22954694]
6. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. *Cell.* 2006; 127:917–928. [PubMed: 17129779]
7. Qiu A, Min SH, Jansen M, Malhotra U, Tsai E, Cabelof DC, Matherly LH, Zhao R, Akabas MH, Goldman ID. Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. *Am J Physiol Cell Physiol.* 2007; 293:C1669–1678. [PubMed: 17898134]
8. Inoue K, Nakai Y, Ueda S, Kamigaso S, Ohta KY, Hatakeyama M, Hayashi Y, Otagiri M, Yuasa H. Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. *Am J Physiol Gastrointest Liver Physiol.* 2008; 294:G660–668. [PubMed: 18174275]
9. Chladek J, Grim J, Martinkova J, Simkova M, Vaneckova J. Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis. *Basic Clin Pharmacol Toxicol.* 2005; 96:247–248. [PubMed: 15733224]
10. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. *Drug Resist Updat.* 2012; 15:183–210. [PubMed: 22921318]
11. Monahan, BP; Allegra, CJ. Antifolates. Lippincott Williams and Wilkins; Philadelphia, PA: 2011. p. 109-138.
12. Visentin M, Zhao R, Goldman ID. The antifolates. *Hematol Oncol Clin North Am.* 2012; 26:629–648. [PubMed: 22520983]
13. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. *Rheumatology (Oxford).* 2008; 47:249–255. [PubMed: 18045808]
14. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. *Mol Cancer Ther.* 2007; 6:404–417. [PubMed: 17308042]
15. Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. *Cancer Res.* 2009; 69:5467–5474. [PubMed: 19549896]
16. Shih, C.; Thornton, DE. Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514). In: Jackman, AL., editor. *Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy.* Humana Press, Inc; Totowa, NJ: 1999. p. 183-201.
17. Kugel Desmoulin S, Wang L, Hales E, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH. Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-*d*]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. *Mol Pharmacol.* 2011; 80:1096–1107. [PubMed: 21940787]
18. Wang L, Wallace A, Raghavan S, Deis SM, Wilson MR, Yang S, Polin L, White K, Kushner J, Orr S, George C, O'Connor C, Hou Z, Mitchell-Ryan S, Dann CE 3rd, Matherly LH, Gangjee A. 6-Substituted pyrrolo[2,3-*d*]pyrimidine thienoyl regioisomers as targeted antifolates for folate

receptor alpha and the proton-coupled folate transporter in human tumors. *J Med Chem.* 2015; 58:6938–6959. [PubMed: 26317331]

19. Wilson MR, Hou Z, Yang S, Polin L, Kushner J, White K, Huang J, Ratnam M, Gangjee A, Matherly LH. Targeting nonsquamous nonsmall cell lung cancer via the proton-coupled folate transporter with 6-substituted pyrrolo[2,3-*d*]pyrimidine thienoyl antifolates. *Mol Pharmacol.* 2016; 89:425–434. [PubMed: 26837243]
20. Salazar MD, Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics? *Cancer Metastasis Rev.* 2007; 26:141–152. [PubMed: 17333345]
21. Xia W, Low PS. Folate-targeted therapies for cancer. *J Med Chem.* 2010; 53:6811–6824. [PubMed: 20666486]
22. Puig-Kroger A, Sierra-Filardi E, Dominguez-Soto A, Samaniego R, Corcuera MT, Gomez-Aguado F, Ratnam M, Sanchez-Mateos P, Corbi AL. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 antiinflammatory/ regulatory macrophages. *Cancer Res.* 2009; 69:9395–9403. [PubMed: 19951991]
23. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. *Cell.* 2006; 124:263–266. [PubMed: 16439202]
24. Vergote I, Leamon CP. Vintafolide: A novel targeted therapy for the treatment of folate receptor expressing tumors. *Ther Adv Med Oncol.* 2015; 7:206–218. [PubMed: 26136852]
25. Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. *Cancer Metastasis Rev.* 2015; 34:41–52. [PubMed: 25564455]
26. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. *J Clin Oncol.* 2013; 31:4400–4406. [PubMed: 24127448]
27. Reddy JA, Bloomfield A, Nelson M, Dorton R, Vetzel M, Leamon CP. Preclinical development of EC1456: a potent folate targeted tubulysin small molecule drug conjugate. *Proceedings AACR.* 2014; 55:199.
28. Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. *Cancer Res.* 2005; 65:11721–11728. [PubMed: 16357184]
29. Deng Y, Wang Y, Cherian C, Hou Z, Buck SA, Matherly LH, Gangjee A. Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity. *J Med Chem.* 2008; 51:5052–5063. [PubMed: 18680275]
30. Wang L, Cherian C, Desmoulin SK, Polin L, Deng Y, Wu J, Hou Z, White K, Kushner J, Matherly LH, Gangjee A. Synthesis and antitumor activity of a novel series of 6- substituted pyrrolo[2,3-*d*]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry. *J Med Chem.* 2010; 53:1306–1318. [PubMed: 20085328]
31. Wang L, Kugel Desmoulin S, Cherian C, Polin L, White K, Kushner J, Fulterer A, Chang MH, Mitchell-Ryan S, Stout M, Romero MF, Hou Z, Matherly LH, Gangjee A. Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-*d*]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits beta-glycinamide ribonucleotide formyltransferase. *J Med Chem.* 2011; 54:7150–7164. [PubMed: 21879757]
32. Wang L, Cherian C, Kugel Desmoulin S, Mitchell-Ryan S, Hou Z, Matherly LH, Gangjee A. Synthesis and biological activity of 6-substituted pyrrolo[2,3-*d*]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier. *J Med Chem.* 2012; 55:1758–1770. [PubMed: 22243528]
33. Mitchell-Ryan S, Wang Y, Raghavan S, Ravindra MP, Hales E, Orr S, Cherian C, Hou Z, Matherly LH, Gangjee A. Discovery of 5-substituted pyrrolo[2,3-*d*]pyrimidine antifolates as dual-acting

inhibitors of glycinamide ribonucleotide formyltransferase and 5- aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: Implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity. *J Med Chem.* 2013; 56:10016–10032. [PubMed: 24256410]

34. Wang Y, Cherian C, Orr S, Mitchell-Ryan S, Hou Z, Raghavan S, Matherly LH, Gangjee A. Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3- *d*]pyrimidine antifolates via cellular uptake by folate receptor alpha and inhibition of de novo purine nucleotide biosynthesis. *J Med Chem.* 2013; 56:8684–8695. [PubMed: 24111942]
35. Golani LK, George C, Zhao S, Raghavan S, Orr S, Wallace A, Wilson MR, Hou Z, Matherly LH, Gangjee A. Structure-activity profiles of novel 6-substituted pyrrolo[2,3- *d*]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors alpha and beta and the proton-coupled folate transporter. *J Med Chem.* 2014; 57:8152–8166. [PubMed: 25234128]
36. Mendelsohn, LG.; Worzalla, JF.; Walling, JM. Preclinical and clinical evaluation of the glycinamide ribonucleotide formyltransferase inhibitors lometrexol and LY309887. In: Jackman, AL., editor. *Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy.* Humana Press, Inc; Totowa, NJ: 1999. p. 261-280.
37. Boritzki TJ, Barlett CA, Zhang C, Howland EF. AG2034: A novel inhibitor of glycinamide ribonucleotide formyltransferase. *Invest New Drugs.* 1996; 14:295–303. [PubMed: 8958185]
38. Bissett D, McLeod HL, Sheedy B, Collier M, Pithavala Y, Paradiso L, Pitsiladis M, Cassidy J. Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. *Br J Cancer.* 2001; 84:308–312. [PubMed: 11161393]
39. Budman DR, Johnson R, Barile B, Bowsher RR, Vinciguerra V, Allen SL, Kolitz J, Ernest CS 2nd, Kreis W, Zervos P, Walling J. Phase I and pharmacokinetic study of LY309887: A specific inhibitor of purine biosynthesis. *Cancer Chemother Pharmacol.* 2001; 47:525–531. [PubMed: 11459206]
40. Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW, Moran RG. Phase I study of (6R)-5,10-dideazatetrahydrofolate: A folate antimetabolite inhibitory to de novo purine synthesis. *J Natl Cancer Inst.* 1993; 85:1154–1159. [PubMed: 8320744]
41. Zhang Y, Desharnais J, Marsilje TH, Li C, Hedrick MP, Gooljarsingh LT, Tavassoli A, Benkovic SJ, Olson AJ, Boger DL, Wilson IA. Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10- (Trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic Acid[†],[‡]. *Biochemistry.* 2003; 42:6043–6056. [PubMed: 12755606]
42. Meanwell NA. Synopsis of some recent tactical application of bioisosteres in drug design. *J Med Chem.* 2011; 54:2529–2591. [PubMed: 21413808]
43. Molecular Operating Environment (MOE). C. C. G. I; 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7: 2014.
44. Dahms TES, Sainz G, Giroux EL, Caperelli CA, Smith JL. The apo and ternary complex structures of a chemotherapeutic target: human glycinamide ribonucleotide transformylase[†],[‡]. *Biochemistry.* 2005; 44:9841–9850. [PubMed: 16026156]
45. Chen C, Ke J, Zhou XE, Yi W, Brunzelle JS, Li J, Yong EL, Xu HE, Melcher K. Structural basis for molecular recognition of folic acid by folate receptors. *Nature.* 2013; 500:486–489. [PubMed: 23851396]
46. Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transportdefective Chinese hamster ovary cells. *J Biol Chem.* 1995; 270:17468–17475. [PubMed: 7615551]
47. Deng Y, Zhou X, Kugel Desmoulin S, Wu J, Cherian C, Hou Z, Matherly LH, Gangjee A. Synthesis and biological activity of a novel series of 6-substituted thieno[2,3- *d*]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. *J Med Chem.* 2009; 52:2940–2951. [PubMed: 19371039]
48. Flintoff WF, Davidson SV, Siminovitch L. Isolation and partial characterization of three methotrexate-resistant phenotypes from Chinese hamster ovary cells. *Somatic Cell Genet.* 1976; 2:245–261. [PubMed: 1028172]

49. Kugel Desmoulin S, Wang Y, Wu J, Stout M, Hou Z, Fulterer A, Chang MH, Romero MF, Cherian C, Gangjee A, Matherly LH. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-*d*]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. *Mol Pharmacol*. 2010; 78:577–587. [PubMed: 20601456]
50. Wibowo AS, Singh M, Reeder KM, Carter JJ, Kovach AR, Meng W, Ratnam M, Zhang F, Dann CE 3rd. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. *Proc Natl Acad Sci U S A*. 2013; 110:15180–15188. [PubMed: 23934049]
51. Wang Y, Mitchell-Ryan S, Raghavan S, George C, Orr S, Hou Z, Matherly LH, Gangjee A. Novel 5-substituted pyrrolo[2,3-*d*]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents. *J Med Chem*. 2015; 58:1479–1493. [PubMed: 25602637]
52. Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG, Grindey GB. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. *Cancer Res*. 1996; 56:2331–2335. [PubMed: 8625328]
53. Assaraf YG. Molecular basis of antifolate resistance. *Cancer Metastasis Rev*. 2007; 26:153–181. [PubMed: 17333344]
54. 2.1.6: L., BioSolveIT. GmbH. Augustin, S; Germany: www.biosolveit.de
55. Molecular Operating Environment (MOE). Chemical Computing Group Inc; 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7: 2013.
56. McNicholas S, Potterton E, Wilson KS, Noble ME. Presenting your structures: the CCP4mg molecular-graphics software. *Acta Crystallogr D Biol Crystallogr*. 2011; 67:386–394. [PubMed: 21460457]
57. Mukherjee S, Balias TE, Rizzo RC. Docking validation resources: protein family and ligand flexibility experiments. *J Chem Inf Model*. 2010; 50:1986–2000. [PubMed: 21033739]
58. Allen WJ, Balias TE, Mukherjee S, Brozell SR, Moustakas DT, Lang PT, Case DA, Kuntz ID, Rizzo RC. DOCK 6: Impact of new features and current docking performance. *J Comput Chem*. 2015; 36:1132–1156. [PubMed: 25914306]
59. Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. *J Chem Theory Comput*. 2015; 11:3696–3713. [PubMed: 26574453]
60. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera—a visualization system for exploratory research and analysis. *J Comput Chem*. 2004; 25:1605–1612. [PubMed: 15264254]
61. Kugel Desmoulin S, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH. Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter. *Mol Pharmacol*. 2012; 82:591–600. [PubMed: 22740639]
62. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem*. 1951; 193:265–275. [PubMed: 14907713]
63. Friedkin M, Roberts D. Conversion of uracil deoxyriboside to thymidine of deoxyribonucleic acid. *J Biol Chem*. 1956; 220:653–660. [PubMed: 13331923]
64. Caperelli CA, Giroux EL. The human glycinamide ribonucleotide transformylase domain: purification, characterization, and kinetic mechanism. *Arch Biochem Biophys*. 1997; 341:98–103. [PubMed: 9143358]
65. Corbett TH, Valeriote FA, Demchik L, Lowichik N, Polin L, Panchapor C, Pugh S, White K, Kushner J, Rake J, Wentland M, Golakoti T, Hetzel C, Ogino J, Patterson G, Moore R. Discovery of cryptophycin-1 and BCN-183577: Examples of strategies and problems in the detection of antitumor activity in mice. *Invest New Drugs*. 1997; 15:207–218. [PubMed: 9387043]
66. Padmanabhan N, Fichtner L, Dickmanns A, Ficner R, Schulz JB, Braus GH. The yeast HtrA orthologue Ynm3 is a protease with chaperone activity that aids survival under heat stress. *Mol Biol Cell*. 2009; 20:68–77. [PubMed: 18946088]
67. Polin, LCT.; Roberts, BJ.; Lawson, AJ.; Leopold, WR., III; White, K.; Kusner, J.; Paluch, J.; Hazeldine, S.; Moore, R.; Rake, J.; Horwitz, JP. Transplantable syngeneic tumors: solid tumors of

- mice. In: Teicher, B., editor. Tumor Models in Cancer Research. Humana Press, Inc; Totowa, NJ: 2011. p. 43-78.
68. Polin L, Valeriote F, White K, Panchapor C, Pugh S, Knight J, LoRusso P, Hussain M, Liversidge E, Peltier N, Golakoti T, Patterson G, Moore R, Corbett TH. Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. *Invest New Drugs*. 1997; 15:99–108. [PubMed: 9220288]
69. Varela-Moreiras G, Selhub J. Long-term folate deficiency alters folate content and distribution differentially in rat tissues. *J Nutr*. 1992; 122:986–991. [PubMed: 1552373]
70. Adams PD, Gopal K, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Pai RK, Read RJ, Romo TD, Sacchettini JC, Sauter NK, Storoni LC, Terwilliger TC. Recent developments in the PHENIX software for automated crystallographic structure determination. *J Synchrotron Radiat*. 2004; 11:53–55. [PubMed: 14646133]
71. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC. PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallogr D Biol Crystallogr*. 2002; 58:1948–1954. [PubMed: 12393927]
72. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr*. 2004; 60:2126–2132. [PubMed: 15572765]
73. Terwilliger TC, Grosse-Kunstleve RW, Afonine PV, Moriarty NW, Zwart PH, Hung LW, Read RJ, Adams PD. Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. *Acta Crystallogr D Biol Crystallogr*. 2008; 64:61–69. [PubMed: 18094468]
74. Kabsch W. Xds. *Acta Crystallogr D Biol Crystallogr*. 2010; 66:125–132. [PubMed: 20124692]
75. Bailey S. The CCP4 suite: programs for protein crystallography. *Acta Crystallogr D*. 1994; 50:760–763. [PubMed: 15299374]
76. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. *J Appl Crystallogr*. 2007; 40:658–674. [PubMed: 19461840]
77. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr D Biol Crystallogr*. 1997; 53:240–255. [PubMed: 15299926]

Figure 1. Structures of classic antifolate drugs, including methotrexate (MTX), pemetrexed (PMX), pralatrexate (PDX), and raltitrexed (RTX).

Figure 2.
Structures of 6-pyrrolo[2,3-*d*]pyrimidine antifolates, 1, 2 and 3.

Figure 3.
Structure of N¹⁰-formyl tetrahydrofolate.

Compound	X
4	NH
5	NCHO
6	NCOCH ₃
7	NCOCF ₃
8	O
9	S

Figure 4.
Structures of 6-substituted pyrrolo[2,3-*d*]pyrimidine antifolates with heteroatom bridge substitutions.

Compound	X	Distance (d)	Angle (a)
3	CH ₂	2.63 Å	109.5°
4	NH	2.52 Å	126.1°
8	O	2.42 Å	111°
9	S	2.88 Å	99°

Figure 5. Distances and bond angle variations predicted by the nature of the bridge at the benzylic position (X)

Bond angles for X = CH₂, O and S obtained from literature.⁴² Distances and angles for X = NH were measured using energy-minimized conformations of compounds with MOE 2014.09.⁴³

Figure 6. Molecular modeling studies with human GARFTase (PDB: 4ZYW).¹⁸
(*Panel A*) Superimposition of docked poses of 1 (green) and 4 (orange) (*Panel B*) Docked pose of 7 (purple). In both panels, GAR is shown in pink.

Figure 7. Molecular modeling studies using the human FR α -crystal structure (PDB: 4LRH).⁴⁵

Panel A, superimposition of the docked pose of 1 (green) with the crystal structure of folic acid (black). *Panel B*, superimposition of the docked pose of 2 (pink) with crystal structure of folic acid (black) (C) Docked pose of 4 (orange).

Figure 8. FR α and FR β binding affinities for compounds 4–9, compared to folic acid, MTX and compound 1.

Results are shown for the relative binding affinities of the (anti)folates with FR α -expressing RT16 and FR β -expressing D4 CHO cells. Relative binding affinities were determined over a range of (anti)folate concentrations and were calculated as the inverse molar ratios of the unlabeled ligands required to inhibit [^3H]folic acid binding by 50%. By this definition, the relative affinity of folic acid is 1. Results are shown as mean values plus/minus standard errors from 3–4 experiments. Detailed experimental methods are provided in the Experimental Section. Abbreviation: FA, folic acid.

Figure 9. Transport competition by 6-substituted pyrrolo[2,3-*d*]pyrimidine analogs for PCFT in R2/PCFT4

Panels A and B: Data are shown for the inhibitory effects of the unlabeled ligands (1 or 10 nM) on [³H]MTX uptake (5 min) with human PCFT-expressing R2/PCFT4 CHO cells at pH 5.5 and pH 6.8. The extent of inhibition in this assay is a reflection of relative PCFT binding affinities for assorted antifolate substrates. Results are presented as average values plus/minus ranges for 2–4 experiments. Results are compared to those for normalized rates in the absence of any additions (“No additions”) and to PCFT-null R2 cells without additions.

Panel C: In the table are shown K_i values for inhibition of [³H]MTX uptake at pH 5.5, as measured by Dixon analysis for 3–8 separate experiments. Experimental details are provided in the Experimental Section. Cpd, compound.

Figure 10. Growth inhibition of KB human tumor cells by 6-substituted pyrrolo[2,3-*d*]pyrimidine antifolates 1, 4, 5, 6, 7, 8 and 9, and protective effects of excess folic acid, nucleosides, or 5- aminoimidazole-4-carboxamide (AICA)

KB cells were plated (4000 cells/well) in folate-free RPMI 1640 medium with 10% dialyzed FBS, antibiotics, *L*-glutamine, and 2 nM LCV with a range of drug concentrations, in presence of folic acid (200 nM), adenosine (60 μ M), thymidine (10 μ M), or AICA (320 μ M). Cell proliferation was assayed with a fluorescence-based assay. Data are representative of at least triplicate experiments. These results are summarized in Table 1. The methods are described in the Experimental Section. Abbreviation: Cpd, compound.

Figure 11. *In situ* GARFTase assay in KB tumor cells treated with 4, 5, 6, 7, 8, and 9
 Inhibition of cellular GARFTase activity by the pyrrolo[2,3-*d*]pyrimidine antifolates was assayed in KB tumor cells. KB cells were treated with drug and [^{14}C]glycine for 16 h, then [^{14}C]formyl GAR was extracted and isolated by anion-exchange chromatography for quantitation. Relative [^{14}C]formyl GAR was expressed as percent of the untreated control as a function of drug concentrations. IC_{50} s were as follows: 2.64 $\pm$ 0.24 nM, **4**; 2.11 $\pm$ 0.37 nM, **5**; 5.58 $\pm$ 0.40 nM, **6**; 4.95 $\pm$ 0.44 nM, **7**; 6.62 $\pm$ 1.63 nM, **8**; and 5.25 $\pm$ 0.60 nM, **9**. For comparison, the IC_{50} for GARFTase inhibitions in KB cells by compound **1**, PMX and LMTX were 1.92 ($\pm$ 0.40) nM (not shown), 30 nM⁴⁷ and 14 nM,⁴⁷ respectively. The methods are described in the Experimental Section. Abbreviation: Cpd, compound.

Figure 12. Crystal structures of FR α /folic acid (Panel A) and FR α /compound **4 (Panel B)** Superimposition of the crystal structure of folic acid with FR α onto the crystal structure of **4** indicates that the truncated 5-membered pyrrolo ring of **4** is compensated via the 3-atom bridge, compared to the 2-atom bridge of folic acid. Thus, the overall dimensions of both folic acid and **4** are comparable, permitting all important interactions with FR α to remain unaltered. The heteroatom in the bridge does not play an important role in binding to FR α for folic acid or **4**. Figure 2S (A, B) shows electron density maps for **4** in complex with FR α .

Figure 13. Crystal structures of human GARFTase

Panel A, crystal structure of **4** (orange); *panel B*, **3**¹⁸ (green) with GAR (pink) in the folate binding pocket of GARFTase. GARFTase is shown in ribbon except for interacting side chains and backbone atoms, which are represented as sticks. For clarity, an alternate side-chain conformation of Arg871 has been removed in *panel B*. Figure 2S (C,D) (Supporting Information) shows electron density maps for **4** with GARFTase.

Figure 14. *In vitro* and *in vivo* efficacies of compounds 4 and 3 toward the IGROV1 ovarian tumor

Upper panel: Representative growth inhibition experiments for IGROV1 tumor cells treated with a range of concentrations of 3 or 4 in the absence (solid symbols and unbroken lines) or the presence (open symbols and broken lines) of 200 nM folic acid are shown. Results for compound 1 are included for comparison. The methods are described in the Experimental Section. *Lower panel:* Female NCR SCID mice (11 weeks old; 20 g average body weight) were maintained on a folate-deficient diet *ad libitum* for 14 days, prior to bilateral subcutaneous tumor engraftment. The mice were non-selectively randomized into 5 mice/group, then compounds 3 (28 mg/kg/inj; Q3dx5) or 4 (96 or 150 mg/kg/inj; Q3dx4) [dissolved in 5% ethanol (v/v), 1% Tween-80 (v/v), 0.5% NaHCO₃ and deionized H₂O; pH 6.5] were administered beginning on day 2. Mice were weighed daily and tumor measurements were recorded twice per week. Results are shown as mean values $\pm$ standard errors. Abbreviation: cpd, compound; Rx, treatment.

Scheme I. Reagents and conditions

(a) Ethanol, reflux, 5 h, 59% ;(b) 33% HBr in CH₃COOH, Br₂, rt, 2.5 h, 33%; (c) (CF₃CO)₂O, rt, overnight, 76%; (d) 2,6-diaminopyrimidin-4(3*H*)-one, DMF, rt, 3 d, 25%; (e) 1N NaOH, rt, 10 h, 88%; (f) *N*-methylmorpholine, 2-chloro-4,6-methoxy-1,3,5-triazine, *L*-Glutamate di-tert-butyl, DMF, 12 h, 60%; (g) CF₃COOH, CH₂Cl₂, rt, 2 h, 74%; (h) (CH₃CO)₂O, rt, 12 h, 47% or (CF₃CO)₂O, rt, 4 h, 76% or (CH₃CO)₂O, HCOOH, 1 h, reflux, 35%.

Scheme II. Reagents and conditions

(a) NaOH, H₂O, 30 min, 80 °C, 52%; (b) Oxalyl chloride, CH₂Cl₂, reflux, 1 h, 79%; (c) Diazomethane, (CH₃CH₂)₂O, rt, 1h; (d) 48% HBr in water, 80 °C, 2 h, 94%; (e) 2,6-diaminopyrimidin-4(3*H*)-one, DMF, rt, 3 d, 31%; (f) 1N NaOH, rt, 12 h, 74%; (g) *N*-methylmorpholine 2-chloro-4,6-methoxy-1,3,5-triazine, *L*-glutamate dimethyl, DMF, 12 h, 42%; (h) 1N NaOH, rt, 4 h, 88%.

Scheme III. Reagents and conditions

(a) NaOAc, H₂O, reflux, 18 h, 54%; (b) LiEt₃BH, THF, 0 °C, 30 min, 75%; (c) CH₃SO₂Cl, DMF, Et₃N, 0 °C, 2 h, 80%; (d) 4-mercapto-benzoic acid methyl ester, K₂CO₃, DMF, rt, 12 h, 37%; (e) 1N NaOH, MeOH, rt, 95–99%; (f) *L*-glutamic acid diethyl ester hydrochloride, *N*-methyl morpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, DMF, rt, 6 h, 60%.

Table 1

IC₅₀s (in nM) for 6-substituted pyrrolo[2,3-*d*]pyrimidine benzoyl antifolates with heteroatom replacements, and classical antifolates in RFC-, PCFT- and FR-expressing cell lines

Proliferation assays were performed for CHO sublines engineered to express human RFC (PC43-10), FRa (RT16), FRβ (D4) or PCFT (R2/PCFT4), and transporter-null (R2) CHO cells,^{29, 46–48} and KB human tumor cells (express RFC, FRa, and PCFT). For the experiments measuring FR-mediated effects, assays were performed in the presence or absence of 200 nM folic acid (results are shown only for KB cells). Results are presented as IC₅₀ values, corresponding to the concentrations that inhibit growth by 50% relative to cells incubated without drug. The data are mean values from 5–16 experiments (± standard errors in parentheses). Some of the data for 1, 2, 3, MTX, PDX, PMX and LMTX have been previously published.^{29–31, 34, 47, 49} Results are also summarized for KB cells for the protective effects of adenosine (60 μM), thymidine (10 μM), or 5-aminoimidazole-4-carboxamide (320 μM). For compounds 4, 5, 6, 7, 8, and 9, folic acid and nucleoside/AICA protection results are shown in Figure 10. Methods are summarized in the Experimental Section. Undefined abbreviations: Ade, adenosine; AICA, 5-aminoimidazole-4-carboxamide; FA, folic acid; ND, not determined; Thd, thymidine.

*Significantly different from compound 4 with RT16 or KB cells, as appropriate (p<0.05); †, significantly different from RT16 with 4 (p=0.0006), 6 (p=0.0026), and 5 (p=0.0001)

Antifolate	RFC		FRa		FRβ		PCFT		RFC/FRa/PCFT		
	PC43-10	R2	RT16	D4	R2/PCFT4	R2	KB	KB (+FA)	KB + Ade/Thd/AICA		
1	649(38)	>1000	4.1(1.6)	5.6(1.2)	23.0(3.3)	>1000	1.7(0.4)	>1000	Ade/AICA		
2	>1000	>1000	6.3(1.6)	10(2)	213(28)	>1000	1.7(0.4)	>1000	Ade/AICA		
3	101.0 (16.6)	273.5 (49.1)	0.31 (0.14)	0.17 (0.03)	3.34(0.26)	288(12)	0.26(0.03)	101(7)	Ade/AICA		
4	510(90)	>1000	3.04 (0.71)	0.62 (0.20)*	87.4(9.9)	>1000	0.32(0.05)	666(46)	Ade/AICA		
5	642(239)	>1000	3.01 (0.57)	0.53 (0.11)†	88.5(13.4)	>1000	2.09(0.72)*	>1000	Ade/AICA		
6	808(124)	>1000	4.87 (0.81)	1.57 (0.53)†	81.7(91)	>1000	2.57(0.60)*	>1000	Ade/AICA		
7	783(109)	>1000	1.08 (0.69)	0.45 (0.11)	109 (26)	>1000	0.56(0.05)*	924(40)	Ade/AICA		
8	641(140)	940(60)	1.89 (0.85)	2.59 (1.17)	57.5(5.8)	>1000	0.34(0.05)	704(73)	Ade/AICA		
9	>1000	>1000	0.51 (0.10)*	0.34 (0.02)	267(19)	>1000	1.66(0.26)*	>1000	Ade/AICA		
MTX	12(1.1)	114(31)	114 (31)	106 (11)	121 (17)	>1000	6.00(0.60)	20(2.4)	Thd/Ade		
PMX	138(13)	42(9)	42 (9)	60 (8)	13.2(2.4)	974 (18)	68(12)	327(103)	Thd/Ade		
RTX	6.3(1.3)	15(5)	15 (5)	22 (10)	99.5(11.4)	>1000	5.90(2.20)	22(5)	Thd		
LMTX	12(2.3)	12(8)	12 (8)	2.6 (1.0)	38.0(5.3)	>1000	1.20(0.60)	31(7)	Ade/AICA		

Table 2
K_i values for inhibition of human GARFTase by 6-pyrrolo[2,3-*d*]pyrimidine heteroatom analogs

GARFTase activity was determined by measuring formation of 5,8-dideazafolate from 10-formyl-5,8-dideazafolic acid using a spectrophotometric assay (295 nm) in the presence of the indicated antifolate. Detailed methods are described in the Experimental Section. Results are shown as mean values $\pm$ standard errors from three replicate assays. The results for compound 3 and PMX were previously reported.¹⁸ Abbreviation; Cpd, compound

Antifolate	K _i (nM)
PMX	1000 $\pm$ 160
Cpd 1	160 $\pm$ 17
Cpd 3	68 $\pm$ 11
Cpd 4	59 $\pm$ 9
Cpd 5	99 $\pm$ 15
Cpd 6	62 $\pm$ 7
Cpd 7	122 $\pm$ 14
Cpd 8	61 $\pm$ 4
Cpd 9	201 $\pm$ 36